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The Report of the Independent Working Group on Drug
Consumption Rooms
This report of the Independent Working Group on Drug Consumption Rooms provides a
detailed examination of whether DCRs should be introduced in the UK.
In the past, the UK Government has rejected calls for the introduction of DCRs, partly
due to the lack of research. However, there is now a much larger evidence base drawn
from projects around the world. The IWG was set up to take an objective look at this
growing evidence base and to consider whether DCRs would have a significant impact
on the particular problems that we face in the UK.
The report reviews the policy context in the UK and how the idea of DCRs articulates
with past and current drug policy. It then examines in detail the particular harms
associated with injecting drug-use in the UK, both in terms of the harm to users but also
the impact on communities. By looking at what the research shows us about the
effectiveness of DCRs, the report then goes on to consider whether they might carry
the potential to reduce the problems caused by drugs in the UK. After considering a
range of potential barriers and concerns, including legal considerations, a number of
recommendations for the future are made.
On the basis of this detailed review of the evidence, the IWG concludes that DCRs offer
a unique and promising way to work with the most problematic users, in order to reduce
the risk of overdose, improve their health and lessen the damage and costs to society.
The IWG therefore recommends that pilot DCRs are set up and evaluated in the UK.
About the Independent Working Group
The IWG was chaired by Dame Ruth Runciman, and included senior police officers,
academics, health professionals and a practicing barrister. Over a 20-month period the
IWG reviewed the published evidence, commissioned new research, heard from
relevant witnesses and visited DCRs abroad.
This publication can be provided in alternative formats, such
as large print, Braille, audiotape and on disk.  Please contact:
Communications Department, Joseph Rowntree Foundation,
The Homestead, 40 Water End, York YO30 6WP.
Tel: 01904 615905.  Email: info@jrf.org.uk
The Report of the Independent
Working Group on Drug Consumption
Rooms
The Joseph Rowntree Foundation has supported this project as part of its programme of
research and innovative development projects, which it hopes will be of value to policy
makers, practitioners and service users. The facts presented and views expressed in this
report are, however, those of the authors and not necessarily those of the Foundation.
Joseph Rowntree Foundation, The Homestead, 40 Water End, York YO30 6WP
Website: www.jrf.org.uk
© Joseph Rowntree Foundation 2006
First published 2006 by the Joseph Rowntree Foundation
All rights reserved. Reproduction of this report by photocopying or electronic means for non-
commercial purposes is permitted. Otherwise, no part of this report may be reproduced,
adapted, stored in a retrieval system or transmitted by any means, electronic, mechanical,
photocopying, or otherwise without the prior written permission of the Joseph Rowntree
Foundation.
ISBN-13: 978 1 85935 470 4
ISBN-10: 1 85935 470 X
A pdf version of this publication is available from the JRF website (www.jrf.org.uk).
A CIP catalogue record for this report is available from the British Library.
Cover design by Adkins Design
Prepared and printed by:
York Publishing Services Ltd
64 Hallfield Road
Layerthorpe
York YO31 7ZQ
Tel: 01904 430033; Fax: 01904 430868; Website: www.yps-publishing.co.uk
Further copies of this report, or any other JRF publication, can be obtained either from the JRF
website (www.jrf.org.uk/bookshop/) or from our distributor, York Publishing Services Ltd, at the
above address.
Membership of the Independent Working Group vii
Acknowledgements ix
Overview x
1 Introduction 1
Definitions and misconceptions 3
The Independent Working Group 4
Structure of the report 6
2 The policy context 7
The Government’s drug strategy 10
The European Union 13
The United Nations and the International Narcotics Control Board 13
IWG conclusions 14
3 Evidence of need 15
Extent of problematic drug use 16
Private and public harms 18
IWG conclusions 30
4 Are DCRs effective? 33
Reaching the target group 35
Impact on health 40
Impact on local communities 54
How do they compare to other interventions and are they cost-effective? 62
Bringing together evidence of need and evidence of effectiveness 64
5 Potential barriers and concerns 66
Legal barriers 66
Ethical concerns 81
Political concerns 83
Local concerns 87
Conclusion 88
6 UK pilots 90
DCR models 90
Contents
DCRs in the UK 95
Evaluation 100
7 Summary, conclusions and recommendations 101
Key findings and conclusions 101
Recommendations 105
Conclusion 108
Notes 109
References 113
Appendix: Terms of reference 125
vi
Ruth Runciman DBE, OBE (Chair) Chair, Central and North
West London Mental
Health NHS Trust
Charlie Lloyd (Manager) Principal Research
Manager, Joseph
Rowntree Foundation
Neil Hunt (Adviser/Secretary) Independent research
consultant
Terry Bamford OBE Previously Chair of the
PCT Board, Kensington
and Chelsea NHS Primary
Care Trust
Rudi Fortson Practising barrister and
author of Misuse of Drugs,
Offences, Confiscation
and Money Laundering
(5th edn)
Kevin Green Detective Superintendent,
Metropolitan Police;
National Co-ordinator,
ACPO Drugs Portfolio
Andy Hayman QPM Assistant Commissioner,
Metropolitan Police; Chair,
ACPO Drugs Portfolio
Professor Neil McKeganey Director, Centre for Drug
Misuse Research,
University of Glasgow
Membership of the
Independent Working Group
vii
Professor Gerry Stimson International Harm
Reduction Association
and Emeritus Professor,
Imperial College London
Professor John Strang Director, National
Addiction Centre, King’s
College London
Dr Nat Wright GP Consultant, HMP
Leeds
viii
Report of the IWG on Drug Consumption Rooms
The IWG would like to thank all the people who have offered help
and advice over the course of its work. Because this amounts to
well over a hundred individuals in the UK and abroad, it is not
possible to mention everyone by name. However, we would
particularly like to thank those who came to London to provide us
with oral evidence: people involved in developing local plans for
DCRs and user group representatives. We would also like to
warmly thank our colleagues in the Netherlands, Germany and
Switzerland for arranging our highly informative visits to DCRs in
these locations and the project workers who patiently responded to
our avalanche of questions. We are also very grateful to
colleagues in Sydney and Vancouver for arranging visits for
individual members to these projects. Finally, we would like to
thank Dagmar Hedrich for her advice and comments on the draft
report and the many others who have taken time to provide us with
references and information.
Acknowledgements
ix
The Independent Working Group on Drug Consumption Rooms
was set up to take an objective, evidence-based approach to a
sensitive question: should problematic drug users be provided with
a place to go to use their illegally obtained drugs in a clean
environment, supervised by medically trained staff? In order to
address this question, the Independent Working Group (IWG)
spent 20 months assessing the evidence. It commissioned
comprehensive reviews of the research on the harms associated
with drugs in the UK and the effectiveness of drug consumption
rooms (DCRs) abroad, and authoritative papers on the national
and international legal situation. Where there were gaps in the
evidence base, research projects were commissioned and the IWG
heard evidence from drug users’ groups and people involved in
developing local plans for DCRs in the UK. Members also visited a
number of DCRs abroad to find out how they operated in practice.
The IWG found that, since the inception of the first DCR in
Switzerland in 1985, there has been a growing acceptance of the
worth of this approach in Europe, with six European countries having
introduced them (Germany, Switzerland, Holland, Spain, Norway
and Luxembourg). DCRs have also been introduced in Vancouver,
Canada, and Sydney, Australia. There are now thought to be in the
region of 65 DCRs operating in 40 cities around the world.
While the benefits of DCRs have been accepted by an increasing
number of governments abroad, the UK Government has hitherto
resisted calls for projects to be implemented here. In 2002, the
Home Affairs Select Committee’s recommendation to introduce
pilot DCRs was turned down by the Government for a number of
reasons, including the lack of evaluation evidence. Since then, the
evidence base has grown considerably and the IWG therefore set
itself the task of examining this evaluation literature in detail and
addressing each of the Government’s arguments against the
Select Committee’s recommendation. In addition, the IWG
reviewed the problems associated with drug use in the UK and
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thereby sought to establish whether we could expect DCRs to have
an impact on the particular situation in this country.
We found that a number of the serious problems associated with
drug use in the UK, such as overdose deaths, blood-borne viruses,
other infections associated with injecting and syringes discarded in
public areas, would all be addressed by DCRs. While one could
not expect DCRs to eliminate such problems completely, provided
they were well designed and well run the IWG would expect DCRs
to have a significant impact on them.
Having reached this conclusion, we then turned to the barriers that
stood in the way of actually setting up DCRs in the UK. While the
legal barriers initially seemed formidable, on closer examination
the UK’s obligations with regard to the United Nations drug control
treaties are far from clear and appear to leave room for the
establishment of DCRs, particularly if they contribute towards the
welfare, rehabilitation and reintegration of users. We saw it as
significant that eight countries, all signatories to international drug
control treaties and, in other respects, committed supporters of the
UN, have introduced DCRs.
Domestic legislation includes a number of areas where those
involved with DCRs, either as users or employees, might be
vulnerable to prosecution. However, we have concluded that the
risk of this happening can be considerably reduced through the
establishment of a set of clear rules governing behaviour within
(and in the immediate area surrounding) a DCR. Moreover, we do
not believe that the establishment of a DCR should take place
without the approval and close involvement of key local agencies,
including the police and the Crown Prosecution Service. If these
criteria are met, we are confident that the benefits that should
accrue, in terms of lives saved, improvements in the health of
users and reductions in the impact of public drug use on
communities, would justify any residual risk.
xi
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The IWG therefore recommends that pilot DCRs are set up in the
UK, founded on local accords between the key agencies. We
recommend that, at least initially, pilots should consist of injecting
rooms only. We believe that well-run needle and syringe exchange
projects offer a promising location for them, as allowing users to
inject safely on the premises is a natural progression from giving
them clean injecting equipment but expecting them to inject
elsewhere. The IWG strongly recommends that these pilots are
rigorously evaluated.
To summarise our case: problematic drug use causes significant
suffering in the UK. We have large numbers of users with little
option but to inject drugs in toilets, alleyways and public parks,
causing damage to themselves and distress and risk to the people
living and working in these areas. We also have the highest
number of drug-related deaths in Europe. We believe that well-run
DCRs would have a beneficial impact on these and other problems
associated with drug use in the UK. They should not be regarded
as a radical policy option but, rather, as a rational and overdue
extension to the Government’s established harm reduction policy
and one that is being introduced in an increasing number of
countries experiencing problems such as our own.
xii
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1The idea of providing drug users with a place to go to use their
illegally obtained drugs is highly contentious and one that has
aroused much passionate debate. It is an idea that lends itself to
extreme responses: on the one hand, many have rejected it out of
hand because it appears to sanction, condone and even
encourage a dangerous, illegal and anti-social behaviour; on the
other, some appear to embrace the concept as the ultimate answer
to ‘the drug problem’. The Independent Working Group on Drug
Consumption Rooms was set up to take an open-minded approach
to this issue and to conduct a dispassionate, evidence-based
analysis of this hotly contested question.
At the time of writing, there are approximately 65 drug consumption
rooms1 (DCRs) in operation around the world but not one of them
in the UK. The UK Government has so far rejected the idea and
has discouraged local agencies from developing DCRs. In 2002,
the Government chose not to accept the recommendation of the
Home Affairs Select Committee that pilot projects should be set up,
partly on account of the lack of evaluation evidence from abroad.
However, over the past four years, much more evidence has been
published about the effectiveness of DCRs operating in other
countries. Moreover, a new breed of DCRs has appeared over this
period, with large-scale, well-resourced, medically supervised
projects having been recently set up in Sydney and Vancouver. It
therefore seemed the right time to revisit these issues and to take
a much more detailed look at the evidence base than has
previously been managed.
While there is considerable variety in the size, nature and function
of DCRs, it may be helpful to provide a brief description of a
‘typical’ project, to give readers a grounding in what they involve.
1 Introduction
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Drug consumption rooms are typically placed in urban areas, close to
established drug markets. Users are often required to be registered to use
the facility and will arrive and give their details to a receptionist. They may
then wait a short time before being allowed to go into another room. This
room will contain a number of booths or injecting spaces with a chair and a
clean table or ledge. All of these will be observable by employed staff. On
entry, users are given a sterile syringe and other items such as a
tourniquet, sterile water for dissolving the drug prior to injection, etc. The
user then goes into the injection area, prepares the drug and injects
himself. Should he have problems injecting the drug, a trained member of
staff can give advice but cannot physically help with the injection process.
Should he collapse, the staff member can go to his assistance. Afterwards,
there is usually a place to sit and relax before leaving the building. Other
medical, nursing, welfare or counselling staff will often be on hand to talk to
those that want help and refer them to other services where appropriate.
DCRs have been set up in Germany, Switzerland, the Netherlands,
Spain, Norway, Luxembourg, Australia and Canada. While there is
some history of earlier, unofficial injecting rooms for drug users, the
first official DCR was opened in June 1986 in Berne, Switzerland
(Hedrich, 2004). By 2003, 12 consumption rooms were in operation
in seven Swiss cities. DCRs were first set up in Germany and the
Netherlands in the mid 1990s and in both cases projects spread
quite rapidly, so that by 2004, 25 DCRs were operating in 14
German cities and 22 rooms in 12 cities in the Netherlands
(Hedrich, 2004). The Spanish experience is more recent, with the
first DCR there set up in 2000, and DCRs in Australia, Canada,
Norway and Luxembourg were set up more recently still. The most
recent DCRs were set up in Oslo and Luxembourg in 2005.
Portugal introduced national legislation which paved the way for
DCRs in 20012, but it is only comparatively recently that a
proposition has been put forward to set up a DCR in Lisbon. A
decision to proceed with this project is likely in the near future3.
However, the UK Government is not alone in resisting calls for the
introduction of DCRs; the Danish Government also recently
rejected such a proposal (Danish Government, 2003).
3Introduction
Definitions and misconceptions
A confusing range of terms has been applied in this field:
‘supervised injecting centres’, ‘safe(r) injecting rooms’, ‘fixing
rooms’, ‘medically supervised injecting centres’, ‘drug consumption
rooms’ and, of course, the term so often used in the past, ‘shooting
galleries’. However, it is vitally important to make some clear
distinctions here.
In this report, the term ‘drug consumption room’ (DCR) is used to
cover any room specifically set up for the supervised, hygienic
consumption of pre-obtained, controlled drugs. This distinguishes
DCRs from ‘crack houses’, ‘shooting galleries’ and other premises
used for the potentially unhygienic consumption of drugs bought at
the same location.
Some DCRs in Europe allow the smoking or inhalation as well as
the injection of drugs. However, the evaluation literature
concentrates in the main on DCRs that only allow injecting of
controlled drugs, supervised by trained staff able to intervene in the
case of overdose. This is also the main focus of this report,
reflecting the chief concern in the UK with injecting drug use, which
is associated with the most serious harms.
A final – and important – definitional distinction concerns the
prescription of heroin. A trial of supervised heroin prescription is
currently under way in England, whereby users go into a medical
facility, receive their drugs and inject them on the premises. Such
programmes have been running for some time in the Netherlands
and Switzerland, with positive results (Stimson and Metrebian,
2003). This is a distinctly different situation to a DCR. The drugs are
legal and prescribed and the user will have had a history of trying
other treatments before receiving a heroin prescription. Before
receiving a heroin prescription a user will most likely have been
treated with methadone (a heroin substitute) and, while failing to
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give up illegal drugs, will have kept in contact with their treatment
agency. Such ‘trusted’ users are therefore far less chaotic than the
typical DCR clientele seen abroad, many of whom are homeless and
experiencing a broad range of social and health problems.
The Independent Working Group
The idea of DCRs has repeatedly cropped up in the public debate
on drugs over the past five years and in December 2003 the Joseph
Rowntree Foundation set up a seminar to discuss the issue. A wide
range of experts from universities, government departments and
drug agencies attended this seminar and there was thought to be
sufficient merit in the idea to justify further exploration of the issues.
As a result, the Independent Working Group (IWG) on Drug
Consumption Rooms was set up and had its first meeting in May
2004. Since then, it met regularly over a 20-month period to consider
the evidence and issues relating to DCRs.
Members were selected in part because they were respected
experts in their particular fields but also because they were thought
to be individuals who would take a dispassionate and evidence-
based approach to the issue. It should be emphasised that, initially,
few of the members had a predefined position on the question of
whether DCRs should be introduced in the UK and people’s
thoughts on the subject changed considerably over the course of
the IWG process and the consideration of the evidence.
The Terms of Reference (see Appendix 1) defined the aims as
follows:
1 To take an objective and evidence-based approach to the
following question, drawing on both the national and
international literature: ‘Is there the potential for DCRs to have a
significant impact on the private and/or public harms associated
with drug use in the UK?’
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2 Should the IWG decide that there is such potential:
 to consider the pros and cons of different models
 to identify the legal, political and practical obstacles to
implementation and seek solutions
 to make recommendations for the development and
evaluation of appropriate demonstration projects.
3 To publish an accessible report summarising the evidence, the
arguments and the recommendations.
The paramount importance of the evidence base was fundamental
to the approach taken by the IWG, reflecting not only the Chair’s
and members’ desires but also the JRF’s general approach of
thoroughly researching social issues before making any
pronouncements on policy. Substantial and authoritative reviews of
the evidence were commissioned wherever possible and these
papers are separately published on the JRF website (http://
www.jrf.org.uk/bookshop/details.asp?pubid=749). Two research
projects were funded to inform the IWG in areas where there was
an almost complete absence of information and relevant questions
were also included in a community survey being conducted as part
of another study. In addition, IWG members have between them
visited DCRs in the Netherlands, Switzerland, Germany, Australia
and Canada. Evidence was also obtained from witnesses who
have been involved in considering local plans for DCRs around the
UK and a drug user consultation was held, involving 13
representatives from drug user groups around the country.
The central question addressed by the IWG was whether there
was the potential for DCRs to have a significant impact on the
private and/or public harms associated with drug use in the UK.
This raises issues about what is meant by ‘potential’ and
‘significant impact’: what was the height of the evidence ‘hurdle’
that DCRs should be expected to clear? Given the considerable
political sensitivities surrounding the issue and the potential for
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DCRs to do harm rather than good, the IWG is clear that there
would need to be strong arguments and compelling evidence
before such an approach could be recommended. However, the
IWG is also mindful that a different level of evidence is required in
considering the worth of ‘piloting’ the approach (setting up
experimental projects that would be carefully evaluated before
making any strategic decision). A recommendation for piloting
would require a lower evidence threshold than a recommendation
for national implementation.
The IWG’s considerations were divided into two phases. First, it
addressed the central question of whether DCRs had the potential
to have an impact on drug use. The main sources of evidence
drawn on to reach this decision were twofold: first, the current level
of need, among both drug users in the UK and the communities
affected by drug use; and, second, the international evidence on
the effectiveness of DCRs. It was thought important to make this
decision first, before proceeding to consider the barriers to
implementing DCRs in the UK. We did not want the fact that DCRs
might be very difficult to set up under current circumstances to
cloud our judgement of whether DCRs were or were not an
intrinsically good idea. The second phase focused much more on
the practicalities: the pros and cons of different models and the
legal, political, ethical and practical obstacles that stood in the way
of implementation.
Structure of the report
The next chapter deals with the UK policy context. Following the
logical order in which the IWG considered the various issues,
Chapters 3 and 4 focus on the evidence of need and the evidence
of effectiveness respectively. Chapter 5 identifies and discusses
the legal, ethical, political and local concerns surrounding DCRs
and Chapter 6 focuses on how pilot projects might be developed
and evaluated in the UK. Chapter 7 contains the IWG’s
conclusions and recommendations.
7In 2002, the Home Affairs Select Committee (HASC) published its
report on the Government’s drug policy. One of its key
recommendations was that:
an evaluated pilot programme of safe injecting houses for
[illicit] heroin users is established without delay and that if, as
we expect, this is successful, the programme is extended
across the country.
(Home Affairs Committee, 2002a, p. 44)
The Home Office’s evidence to the HASC had already made clear
the Government’s opposition to DCRs on a number of grounds
(Home Affairs Committee, 2002b, pp. 226–7):
 ‘International legal position means that the rooms could be (but
have not been) open to legal challenge.
 The Government could be accused by the media and others of
opening “drug dens”.
 No guarantee that public or political tolerance will be the same
as Switzerland.
 Will directly increase health service costs as they would be a
new service provision requiring additional capital and revenue
costs.
 Still leave the possibility of unsafe injecting during the hours
they are closed.
 There may be problems in some areas on occasion with drug
dealers congregating near to venues, leading to reduced local
tolerance for the presence of injecting rooms in their
neighbourhood.
2 The policy context
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 Likely to raise the issue of policing low-level dealing in the
vicinity of injecting rooms.’
The Home Office statement went on to explain that ‘the current
Government position is that injecting rooms for illicit drugs should
not be introduced in this country whilst we have no evaluations of
those developed in other European countries’ (Home Affairs
Committee, 2002b, p. 227). Consistent with this position, the
Government’s response to the published HASC report was that it
would develop its policy of supervised consumption for those
prescribed heroin but not for those who have not been prescribed
heroin.
Some of these themes were repeated in a later interview with the
then Home Secretary, David Blunkett:
Where there are ‘shooting galleries’ I am ruling those out
because at the moment we need much stronger evidence that
firstly, they would ease the problem and secondly that they
wouldn’t cause such a backlash and undermine our
progressive step-by-step policy in terms of prescribing. And
thirdly, that people wouldn’t try and develop these as a type of
attraction.
(Druglink, 2003, p. 10)
Some six months after the first meeting of the IWG, in November
2004, the Home Office commented on plans for a proposed mobile
DCR in Cardiff in the following terms:
The UK will not contravene or undermine UN conventions or
the Misuse of Drugs Act. We believe facilities for supervising
the consumption of illegal drugs would fall foul of these.
Therefore, no authority could be given to the piloting of
initiatives to supervise the consumption of illegal drugs.
(http://news.bbc.co.uk/1/hi/wales/4053921.stm)
The policy context
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These same words were used more recently as part of the
Government’s progress report on action taken on the HASC’s drug
policy recommendations (House of Commons, 2005):
We need to be careful to distinguish between facilities to
supervise the consumption of prescribed drugs and new
initiatives to supervise consumption of illegally acquired drugs.
The supervision and consumption of prescribed drugs in front
of trained staff is a well-established practice in England.
However, the UK will not contravene or undermine UN
conventions or the Misuse of Drugs Act. We believe facilities
for supervising the consumption of illegal drugs would fall foul
of these. Therefore, no authority could be given to the piloting
of initiatives to supervise the consumption of illegal drugs.
Several countries are piloting injecting rooms for illegal drugs
and early evaluation does seem to indicate that such facilities
can prevent overdose fatalities and reduce harm to drug
misusers. However, such facilities do vary in style and content
and most evaluations have not adequately looked at the
impact of such facilities on local communities. Evaluation
reports suggest that they can act as a magnet to drug
misusers and dealers and require very careful management to
minimise dealing and violence.
There is therefore a clear set of objections that underlay the
Government’s original rejection of the idea of DCR pilots in 2002
and some of these have been reiterated in more recent
commentaries. Most of these objections will be reconsidered in
more detail in Chapter 5, after the research evidence has been
assessed. However, the Government’s central concern about the
weakness of the evidence base will be briefly dealt with here
because of its relevance to the need for the IWG. A considerable
number of evaluation and research papers have been published
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since the HASC report, of which perhaps the most important is an
extensive and authoritative review of the evidence carried out by
the European Monitoring Centre for Drugs and Drug Addiction1
(Hedrich, 2004). A number of important publications have also
emerged from the well-conducted evaluations of the new facilities
in Sydney and Vancouver, including a very detailed and
authoritative evaluation report on the Sydney Medically Supervised
Injecting Centre (MSIC). As the more recent government response
to the HASC recommendations appears to acknowledge, the
evidence base is certainly much stronger in 2006 than it was in
2002. Indeed, as has already been stated, this has been a strong
imperative for setting up the IWG.
The Government’s drug strategy
The historical context
In the past, the UK has been in the vanguard with regard to the
introduction of harm reduction measures and, as a consequence,
has been remarkably successful in controlling the spread of HIV
infection among people who inject drugs. The UK’s first and only
major epidemic of HIV among injectors occurred in Edinburgh and
Dundee in the early 1980s. By 1985 and 1986 there was
increasing concern in government and in drugs services that HIV
might rapidly spread to the rest of the UK’s injectors (Stimson,
1995). There followed the rapid introduction of a range of harm
reduction measures. This included syringe exchange, the social
marketing of safer drug use and expansion of methadone
prescribing, coupled with improved access to services and
treatment, voluntary testing and counselling for HIV and outreach
to drug users in the community.
These developments were given momentum by the report of the
Advisory Council on the Misuse of Drugs, AIDS and Drug Misuse:
The policy context
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We have no hesitation in concluding that the spread of HIV is
a greater danger to individual and public health than drug
misuse ... We must therefore … work with those who continue
to misuse drugs to help them reduce the risk involved in doing
so, and above all the risk of acquiring or spreading HIV.
(ACMD, 1988, para. 2.1)
In international terms, HIV prevention among injecting drug users
in the UK has been a public health success story: the prevalence
of HIV declined through to 1992, and the proportion of injectors
with HIV has stayed around 2 per cent or less over much of the
period 1993 to 2004 (but with an indication of a recent rise: Hope
et al., 2005). To put this in context: there are many cities around
the world where the proportion of injectors with HIV is in the range
of 40 to 60 per cent. A key to this success has been government
commitment and allocation of resources to harm reduction. The UK
led the world in demonstrating the feasibility, acceptability and
effectiveness of harm reduction.
The current Drug Strategy
Over the past ten years, there has been an increasing emphasis in
government strategies on reducing the harms associated with drug
use. The lead aim of the Updated Drug Strategy 2002 is ‘Reducing
the harm that drugs cause to society – communities, individuals
and their families’ (Home Office, 2002a, p. 6). This focus is
reflected in the priority accorded to reducing drug-related deaths by
20 per cent by 2004.2 Since then, the number of drug-related
deaths has become a key element of the Drug Harm Index, which
has been developed to measure the Government’s Public Service
Agreement target of reducing drug-related harm (MacDonald et al.,
2005). There is an even stronger emphasis on harm reduction in
the recent updated Models of Care report from the National
Treatment Agency (NTA, 2005), which advocates ‘a far greater
emphasis on the need to reduce drug-related harm including risks
Report of the IWG on Drug Consumption Rooms
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of BBV infection, overdose and other infections at all points in the
treatment journey’.
As will be described, two of the central aims of DCRs are to
prevent overdose and reduce the transmission of blood-borne
viruses. If they were successful in this capacity, they would
contribute to two major aims of government policy.
As well as seeking to reduce drug-related deaths and the
transmission of blood-borne viruses, the Government’s Drug
Strategy seeks to improve the general health of drug users and
improve access to treatment. Again these are two areas where,
were DCRs able to deliver on their aims, they would contribute to
the achievement of some of the Government’s strategic goals.
Scotland
The Scottish strategy, Tackling Drugs in Scotland: Action in
Partnership, has a similar emphasis on harm reduction, aiming to
reduce drug-related deaths and the health risks associated with
drug use and the sharing of injecting equipment. However, the
issue of drug-related deaths has recently received particular
attention, following the highest ever recorded number of such
deaths in 2003. A number of official inquiries and reports followed.
The report of the Association of Drug Action Teams on strategies to
prevent drug-related deaths explicitly referred to the potential for
‘safer injecting rooms’ to prevent deaths (Association of Drug
Action Teams in Scotland, 2005). This was picked up by the
Scottish Advisory Committee on Drug Misuse in its report on the
issue, where the recommendation was made that the Scottish
Executive ‘closely monitor developments taking place outwith
Scotland such as supervised consumption rooms’ (Scottish
Advisory Committee on Drug Misuse, 2005, p. 12). In a recent
response to the SACDM report, the Scottish Executive has agreed
to monitor the use of DCRs abroad (Scottish Executive, 2005).
The policy context
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The European Union
The EU Drugs Action Plan (2005–2008) makes no explicit
reference to DCRs but has a strong focus on harm reduction, with
objectives covering the need for access to harm reduction
services, programmes to prevent the spread of blood-borne viruses
and interventions to prevent drug-related deaths. The Action Plan
states that the ‘reduction of drug related deaths [is] to be included
as a specific target at all levels’ (Council of the European Union,
2005, p. 13).
The United Nations and the International
Narcotics Control Board
The UN position is complex. The British Government is a signatory
to the three UN Conventions governing drug trafficking and other
aspects of international and domestic drug policy. However, the
general language used in these Conventions, and the broad range
of possibly relevant sections contained within them, makes
interpretation difficult (Fortson, 2006a, 2006b3). Accordingly,
commentators have taken a variety of different positions on the
implications of the UN Conventions for DCRs. The International
Narcotics Control Board (INCB), the independent body responsible
for monitoring member states’ compliance with the Conventions, is
confident that DCRs do indeed contravene them. Each year it
produces a report summarising relevant developments around the
world and each year since 1999, the INCB has expressed its
opposition to DCRs. However, this has not prevented eight
countries, each of which has signed at least two of the
Conventions, from developing DCRs. These issues are considered
in more detail in Chapter 5, which examines the legal impediments
to setting up DCRs.
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IWG conclusions
The IWG recognises and welcomes the fact that the UK
Government’s Drug Strategy has increasingly focused on harm
reduction, alongside other priorities. This emphasis on harm
reduction means that the objectives of DCRs actually chime well
with the Government’s current drug policy.
When the idea of introducing DCRs was last considered by the
Government in 2002, a proposal to pilot DCRs was rejected on a
number of grounds, an important one of which was the lack of
evidence. The past four years have witnessed a dramatic increase
in the evaluation literature and there is consequently a need to
reconsider what the evidence base can tell us about the
effectiveness of DCRs. It is also important to consider the issue of
‘need’: whether the drug-related problems experienced in the UK
are of a scope and nature that might be addressed by DCRs. The
next chapter turns to this question.
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DCRs have been set up abroad in response to a range of concerns
and needs. These can be categorised as public harms which affect
communities, such as discarded syringes in public parks and
toilets, and private harms which affect individuals, such as
overdose death and blood-borne viruses.1 The public nuisance
caused to residents and businesses close to drug markets has
been a crucial factor leading to the setting up of DCRs in
Swizerland, Germany and the Netherlands (Hedrich, 2004). The
story of Platzspitz or ‘Needle Park’ in Zurich, Switzerland, is an
example of how public concern led to a sequence of events
culminating, among other things, in the establishment of a DCR
(MacCoun and Reuter, 2001). Large numbers of drug users began
to use this park in the centre of Zurich during the 1980s. The
increasing numbers of drug users and amount of drug-related litter
in this public park eventually led to its closure, the relocation of
users to the local train station and finally the setting up of a DCR.
The focus on public nuisance has perhaps been strongest in the
Netherlands, where local concerns about drug taking in public
places have been pivotal in the decision to implement DCRs.
Public order is clearly at the centre of the Dutch policy on DCRs
(Hedrich, 2004).
The private harms, in particular overdose deaths, associated with
drug use have also been a driving force behind the setting up of
DCRs in other countries. These appear to have been key to the
setting up of projects in Norway, Spain and Canada and were also
influential in their establishment in Switzerland (Hedrich, 2004;
Skretting, forthcoming). The context in which DCRs were
established in Sydney, Australia, was more idiosyncratic: rooms
used by sex workers were increasingly being rented to drug users
as illegal shooting galleries. Drugs were also being supplied from
these rooms and police corruption surrounding their control was
uncovered as part of a wider inquiry into police corruption (van
Beek, 2004). The Royal Commission report resulting from this
inquiry recommended that consideration be given to the
3 Evidence of need
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establishment of ‘safe, sanitary injecting rooms’ (quoted in van
Beek, 2004, p. 3).
In considering the question of the need for DCRs in the UK, the
IWG finds it significant that, while there were known to be high
levels of injecting drug use in particular areas of the UK, these did
not appear to be associated with the sort of extensive public
injecting that had been instrumental in the setting up of some of the
European DCRs. A central question was therefore whether there
was evidence of significant public injecting and associated
nuisance in this country.
Recognising the other premise put forward for the establishment of
DCRs, the private harms to the user, the IWG was also concerned
to bring together the evidence on overdose deaths, the
transmission of blood-borne viruses and other health harms
caused by injecting drug use.
Extent of problematic drug use
Within the UK the information on the extent of problematic drug
use2 is far from complete. For example, research is currently only
recently under way to provide the first ever estimates of the extent
of problematic drug use at the national and local level within
England. To obtain a measure of the extent of problematic drug
use in the UK as a whole, therefore, it is necessary to knit together
a range of prevalence estimates from different studies conducted
at different times. The most up-to-date estimate of national
prevalence relates to Scotland where it has been estimated that
there were 51,582 problematic drug users in 2003 (Information and
Statistics Division, 2004). The next most recent estimate relates to
England where it was estimated that there were 287,670
problematic drug users in 2001 (Frisher et al., 2004). An estimate
for Northern Ireland has been produced for 2000/1 which placed
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the figure at 828 (McElrath, 2002). Estimates for Wales were
derived in 1994 (Wood et al., 2000) and are now thought to be
obsolete.3 If it were assumed overall that the prevalence rate for
Wales was the same as that for England (8.91 per 1,000
population aged 15 to 64) this would mean that the figure for the
UK overall would be in the region of 357,000 problematic drug
users. The recently published report from the European
Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
shows the prevalence of problematic drug use in the UK to be
higher than for any of the other countries represented within
the European Union (EMCDDA, 2005).
An important developing feature of problem drug use in the UK is
the increasing use of crack cocaine. Surveys have shown
increasing levels of crack use in the UK and increasing numbers of
crack users are presenting themselves to treatment services
(Home Office, 2002b). Crack is frequently used alongside heroin:
sometimes simultaneously in a single injection in the form of
‘speed-balling’ but more often as separate (but reinforcing)
elements of a drug habit. While cocaine and crack cocaine are
more often inhaled, they can also be injected and primary cocaine
injectors tend to inject more frequently than heroin users (Friedman
et al., 1990; Mann et al., 1992; McCoy and Inciardi, 1995) and
report higher levels of risk behaviours (Health Protection Agency,
2005). Furthermore, users of both crack and heroin are associated
with particularly high rates of offending among those arrested by
the police (Holloway and Bennett, 2004).
The prevalence of injecting drug use is known to vary considerably
around the UK and is also much more prevalent among particular
groups, such as the homeless (Fountain et al., 2003a, 2003b) and
sex workers (McKeganey and Barnard, 1996; Ward et al., 2000).
Projects and initiatives therefore need to be tailored to the
particular drug problems arising at the local level.
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Private and public harms
It was clear from the IWG’s initial discussions that DCRs had the
theoretical potential to have an impact on both private and public
harms. A review was commissioned to gather the relevant UK
evidence (Hunt, 2006a).
Private harms
The key private harms were identified as: the risk of drug-related
deaths and other emergencies; the transmission of blood-borne
viruses; the other health risks associated with injecting; and
untreated drug use. This section of the report addresses each of
these in turn and concludes with a summary of what is known
about homeless users and public injectors, overlapping groups that
are at considerably greater risk of private harm and which are often
targeted by DCRs abroad.
1 Overdose
As discussed in the last chapter, preventing overdose is an
important aim of the current UK Drug Strategy and has been one of
the primary goals of DCRs in countries including Germany,
Australia and Canada.
‘Overdose’ most commonly occurs when heroin or other opiates
depress the respiratory system, starving the brain of oxygen. It is
now widely recognised that fatalities often arise when opiates are
used in conjunction with other depressants, notably alcohol and
benzodiazepines (Darke and Zador,1996). By bringing drug use
under the direct supervision of trained practitioners, DCRs provide
an environment in which early recognition of overdose and
intervention are possible and deaths can be averted.
Since 1996, the UK has consistently reported the highest
number of drug-related deaths in Europe (EMCDDA, 2005),
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although the number has been declining in recent years. In much
of Europe problem drug users have an annual risk of mortality of
over 1 per cent, which is around 15 times higher than the risk for
the general population of young adults (aged 15–44), potentially
contributing over 10 per cent of young adult mortality (Hickman
et al., 2003; Bargagli et al., 2005).
‘Overdose’ is not treated as a distinct category within mortality data
published either by the Office for National Statistics or the National
Programme on Substance Abuse Deaths – np-SAD (Office for
National Statistics, 2005; Ghodse et al., 2005). However,
‘overdose’ deaths contribute substantially to these and there is now
an agreed protocol for monitoring drug-related deaths that
excludes deaths that would largely be outside the province of drug
services, e.g. paracetamol overdose.
Fatal and non-fatal overdoses are relatively common occurrences
among heroin injectors. In 2003, there were 1,388 drug-related
deaths in England and Wales, of which 591 involved heroin and
morphine (Office for National Statistics, 2005). Using a different
monitoring system, the National Programme on Substance Abuse
Deaths reported a similar number of deaths in 2004: 1,372
(Ghodse et al., 2005). In Scotland in 2004, there were 356 drug-
related deaths, of which 225 were associated with heroin or
morphine (General Register Office for Scotland, 2005); in Northern
Ireland there were 21 deaths associated with heroin in 2000
(Registrar General, 2001). Non-fatal overdose is more common,
with somewhere in the region of 20 to 40 per cent of injecting
heroin users reporting ever having such an experience (Gossop
et al., 1996; Powis et al., 1999). Non-fatal overdoses can be
associated with brain damage and a range of other physical
injuries. Both fatal and non-fatal overdoses frequently result in
ambulance call-outs and treatment in hospital. However, there are
no national statistics by which to measure the extent of this
problem. While local data are available, the IWG emphasises the
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need for standardised ambulance call-out statistics that can be
collated at the national level. This is a significant weakness in the
evidence base.
One of the central aims of DCRs is to intervene early on in
overdose incidents, in order to prevent physical damage and
death. Whether or not they are successful in achieving this aim is
considered in the next chapter.
2 Transmission of blood-borne viruses
It is well known that the shared use of syringes and other injecting
paraphernalia can lead to the transmission of blood-borne viruses,
including HIV and hepatitis B and C. In order to combat the spread
of HIV in particular, the provision of clean syringes has become a
major part of drug policy over the past two decades. HIV
prevalence among people attending drug services in 2004 was 3.9
per cent for those in London and 0.6 per cent for those elsewhere
in England and Wales (Health Protection Agency, 2005), much
lower than in many other Western European countries (EMCDDA,
2005). The number of new diagnoses of HIV infection among
injecting drug users has been decreasing since the early 1990s
(Health Protection Agency, 2005) but a recent study has found a
higher than expected rate of HIV antibodies among newer
injectors, suggesting that historically low rates may now be
beginning to climb (Judd et al., 2005).
There are indications of an increase in the prevalence of hepatitis
C since the late 1990s. According to the Unlinked Anonymous
Prevalence Monitoring Programme (UAPMP) survey, prevalence
among more recent initiates (those who began injecting in the
previous three years) in England and Wales has increased from 12
per cent in 1998 to 20 per cent in 2004 (Health Protection Agency,
2005). Prevalence among all users stands at 41 per cent (Health
Protection Agency, 2005). The significance of this problem at the
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policy level is illustrated by the existence of the Hepatitis C Action
Plan (Department of Health, 2004), which focuses on how to
respond to this ‘silent epidemic’. If left untreated, hepatitis C can
cause serious liver disease in some patients, including cirrhosis
and liver cancer. The prevalence of hepatitis B is lower (around 20
per cent) but can likewise lead to liver disease and cancer and, in
some cases, immediate death.
Between 1992 and 1997, needle and syringe sharing in England
and Wales stayed at a relatively steady rate, with just below 20 per
cent of current users reporting sharing in the previous month. In
1998, the rate increased to around 30 per cent and has since
remained at around this level (Health Protection Agency, 2005).
Recent research suggests that between three-quarters and four-
fifths of drug injections involve previously used needles, although
this does not necessarily imply sharing (Hickman et al., 2004b) as
people may reuse their own needles.
Where users do become infected with blood-borne viruses, there
are good reasons for them to be aware of this fact: it may
encourage them to look after their own health and take extra
measures to prevent transmission of the virus to others. The
evidence shows that approximately half the drug users infected
with the hepatitis C virus and a similar proportion of those infected
with HIV appeared to be unaware of their infection in 2004 (Health
Protection Agency, 2005).
While the majority of people can be prevented from contracting
hepatitis B through a course of three vaccinations, many drug
agencies do not routinely offer this service and less than half of
injecting drug users have been vaccinated (Hunt, 2006a).
DCRs aim to prevent the transmission of blood-borne viruses by
providing sterile syringes and injecting paraphernalia. They can
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also aim to intervene if users try to share injecting equipment on
the premises or try to divide up drugs using potentially infected
syringe barrels. They may also provide opportunities for testing a
particularly marginalised group of users for the presence of blood-
borne viruses and vaccinating them against hepatitis B, either
directly on site or through referring to other services.
Finally, there is also the potential to provide sexual health advice
and condoms through DCRs, thus contributing to efforts to combat
the transmission of blood-borne viruses through unsafe sex. While
reference is made to sexual health advice in the Sydney MSIC
evaluation (MSIC Evaluation Committee, 2003), there is generally
limited information on this issue in the evaluation literature.
3 Other health risks
DCRs often target more marginalised drug users, who may be
injecting in public places. In such situations it is often very difficult
to maintain a clean injecting environment. Furthermore, the need to
inject covertly, coupled with the onset of withdrawal symptoms, can
often lead to injections taking place in poor light and great haste.
Such circumstances increase the risk of failed injection attempts
and bacterial or fungal infection through injection sites on the body.
Research suggests that even in the general population of injecting
drug users (rather than those specifically injecting in public places),
hand washing is infrequent and swabbing an injection site prior to
injection almost equally rare (Health Protection Agency, 2005).
Accordingly, one study (Stone et al., 1990) conducted at an
emergency department in Glasgow found that almost a third of the
488 drug users attending had either abscesses or cellulitis
(inflammation of the skin caused by bacterial infection). A more
recent survey of injecting drug users found that three-fifths
reported a possible infection at an injecting site in the past year
and a third reported an abscess, sore or open wound at an
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injection site over a similar period. Half of those reporting such an
infection had sought medical attention (Health Protection Agency,
2005). Another common problem stemming from poor injecting
practice is damage to and collapse of veins. This can lead to more
dangerous injecting in the neck and groin which, in turn, is
associated with risk of deep vein thrombosis and impaired blood
circulation to the brain.
More uncommon health problems associated with unhygienic
injecting include wound botulism, tetanus and other clostridial
infections (Hunt, 2006a).
As a result of such health problems (and overdose incidents), drug
users are frequently treated in hospital. It was recently reported
that 6.9 per cent of all the patients attending an emergency
department in South West England had attended for drug-related
reasons (Binks et al., 2005). The majority of drug-related problems
were acute injuries (often assault), overdose and the medical
complications of drug use.
4 Untreated drug use
While not a ‘private harm’ in its own right, the continuation of
problem drug use without treatment is likely to be associated with
the problems listed above, along with many others. It is clearly the
case that, at any one point in time, a large proportion of injecting
drug users are not in treatment: recent research suggests as many
as three in four (Hickman et al., 2004b).
DCRs offer the opportunity to refer users to treatment agencies.
They also offer the opportunity to provide support in some of the
other areas of users’ lives that are intimately connected with their
drug use, such as accommodation, general health and counselling.
There has been a strong emphasis on integrating treatment within
wider systems of social support in the National Treatment Agency’s
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Treatment Effectiveness Strategy (NTA, 2005) and DCRs could
provide the opportunity to deliver a similar socially integrative
approach to those not yet in the treatment system.
5 Homelessness and injecting in public places
A substantial proportion of rough sleepers are also problem drug
users: research showed that around half of a sample of 389
homeless people in inner London had injected in the previous
month and 36 per cent were assessed as being dependent on
heroin (Fountain et al., 2003a, 2003b). Many more dependent drug
users are likely to be based in hostels.4
There is also evidence that a significant proportion of users
accessing treatment or admitted to hospital are homeless. The
National Treatment Outcome Research Study (NTORS) showed
that 7 per cent of its cohort of over 1,000 drug users starting a new
episode of treatment were homeless (Gossop et al., 2001).
Similarly, the Drug Outcome Research in Scotland (DORIS) study
identified 15 per cent of users initiating treatment as being
homeless (McKeganey et al., 2005). Neale (2001) found that 32
per cent of a sample of 200 users admitted to accident and
emergency departments in Scotland following an overdose were
homeless.
While there is limited research on the issue, it is clear that
homeless users are at particularly high risk in regard to the health
problems and dangers referred to above, as well as a range of
other risks, such as the risk of being a victim of theft or violent
attack. Research conducted in the early 1990s showed that
homeless injectors were likely to use more drugs more frequently,
were less likely to be engaged in treatment, were more chaotic and
shared injecting equipment more often than the rest of the sample
(Klee et al., 1990; Klee, 1991).). Recently published qualitative
work undertaken in the UK amongst homeless injecting drug users
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with a confirmed diagnosis of hepatitis C has highlighted the health
risks of public injecting. Users reported picking up and using
needles which had been discarded on the street; preparing drugs
with water drawn from toilets, puddles or discarded bottles; and
using discarded cigarette ends as filters (Wright et al., 2005).
By definition, homeless drug users are likely to be injecting in
public places. Homeless users living in hostels are often not
allowed to inject on the premises (although the IWG did hear
evidence from its meetings with local projects and with users that
this is not always the case). Users will therefore often have to
leave their hostels in order to inject in the local vicinity. Those
sleeping rough will inevitably be forced to use in public places. A
recent survey sample of 113 homeless injecting drug users
included a question on the location of their last injection. Sixty-four
per cent reported that their last injection had been in a public place,
mostly streets, parks and public toilets (Judd et al., 2005).
While homeless people are more likely than others to inject in
public places, there is some research to suggest that they are not
the only group doing so. Of the 56 public injectors included in a
study by Klee and Morris (1995), only 22 were homeless.
Recognising that the fieldwork for the latter study was conducted in
1992, the IWG was concerned that there was no more recent
research on the key question of the extent and nature of injecting
in public places. A study was therefore commissioned to address
this issue. This research is outlined in the box (for a full account
see Hunt et al., forthcoming).
IWG research on syringe exchange users
This study focused on a sample of 398 drug users obtaining sterile
injecting equipment at a number of needle exchange projects and
pharmacies in Glasgow, Leeds and London. The sample was mostly male
Continued overleaf
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This research demonstrates for the first time that public injecting is
very common among drug users accessing syringe exchange
facilities. While there are inevitably problems with extrapolating
from one study conducted in three cities to the national level, it can
be concluded with some confidence that, in England alone,
there are tens of thousands of injecting episodes per month
occurring in public places5.
A key, largely unanswered, question in this field is the degree to
which being homeless or a public injector confers a greater risk of
overdose. Klee and Morris (1995) found that public injectors had a
high risk of non-fatal overdose. A similar conclusion was reached
by the Advisory Council on the Misuse of Drugs (ACMD) in their
report on drug-related deaths (ACMD, 2000). Having referenced a
number of studies conducted elsewhere in Europe, they concluded
that:
(82 per cent) and white (91 per cent), with an average age of 34.
Respondents were asked where they had injected over the past week and
42 per cent responded that they had injected at least once in public areas,
including public toilets, streets and parks. The extent of public injecting was
clearly related to accommodation status. While 98 per cent of the users
sleeping rough (n = 46) had injected in a public place in the past week, this
was true of 49 per cent of hostel dwellers (n = 132) and 24 per cent of
those living in their own accommodation. Thus, rough sleepers were
considerably more likely to inject in public places than any other group and
hostel dwellers were twice as likely to do so as those living in their own
home. However, the fact that nearly a quarter of the people living in their
own home reported having injected in public in the past week is significant,
given that they were the largest group attending the needle exchange
facilities. Public injecting is therefore certainly not the sole preserve of the
homeless.
The sample was also asked about the proximity of their main drug market
to where they lived and just over half lived within half a mile. Just under a
quarter lived around a mile from their main drug market; the other quarter
two miles or more.
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We think that this non-UK literature probably carries relevance
for this country, and here too homelessness and injecting
outdoors are likely to be risk factors [for drug-related death].
(ACMD, 2000, p. 25)
DCRs tend to target homeless users and other users who are
injecting in public places. These are groups that appear to be at
particularly high risk of drug-related health problems and overdose.
Lastly, it has become clear to the IWG that, beyond the health
problems that can be reliably measured, there is a great loss of
dignity associated with injecting drugs in run-down backstreets and
alleyways. There is undoubtedly much mental anguish experienced
by those users who need to use in such dangerous and depressing
places. This seems additionally significant in that, without some
level of self-esteem, it is hard to see such users making a realistic
attempt to address their multiple problems, including seeking to
overcome their dependence on illegal drugs.
Public harms
While the private harms referred to above primarily affect the
individual concerned, they also affect others around them and will,
in addition, have an economic impact in terms of ambulance call-
outs and hospitalisation. The potential for DCRs to influence
ambulance call-out rates and treatment following overdose will be
addressed in the next chapter. More relevant here is the issue of
the social impact of injecting in public places – including the
associated drug-related litter.
Use of drugs in public places has a direct effect on those who
witness actual drug-using episodes and a wider, more indirect effect
in terms of the drug-related litter often left in public places, including
syringes, swabs and the packaging that contains these tems. The
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IWG is surprised by the dearth of information and research in this
field, given the media coverage of such issues and the obvious
public concern relating to discarded syringes and associated
‘needlestick’ injuries. The only substantial previous research is the
Environmental Campaigns (ENCAMS) survey of drug-related litter
which was carried out in 1998, 2001 and 2004 (ENCAMS, 2005).
This showed a rapid increase in the annual number of needles
collected in England over this period: from 3,570 in 1998/9 to
147,345 in 2003/4. While caution needs to be exercised in
interpreting these statistics, given that local collection and recording
procedures are inevitably variable and the proportion of local
authorities responding to the survey has never been high, the recent
report is confident in concluding that ‘the quantity of needles
found is increasing dramatically year on year’ (ENCAMS, 2005,
p. 34). It is clear from this report that the problem is an increasingly
widespread one, with growing numbers of rural and seaside
authorities reporting finds. The sites reported by most local
authorities were parks/playing fields, public toilets, residential areas,
car parks and footpaths. Over the three-year period up to 2004 there
had been 169 recorded needlestick injuries, the majority of those
injured being local authority employees (ENCAMS, 2005).
While this survey is very useful in giving some sort of indication of
the size and spread of the problem, it does not provide an
understanding of the impact of discarded syringes and other drug-
related nuisance on local communities and businesses. It was
therefore decided to commission a research project specifically to
address this gap in the knowledge base. Additionally, some items
were included in a community survey which was conducted as part
of another study (May et al., 2005).
1 Community survey
A street survey was conducted with a total of 717 residents in four
different sites as part of a JRF study of the impact of drug dealing
on communities (May et al., 2005). Some questions were included
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in this survey to inform the IWG’s deliberations. Of this sample, 17
per cent said they had seen someone injecting heroin or crack and
29 per cent said that they had found discarded needles. The
communities where this research took place were selected
because they were associated with drug dealing, so these findings
could not be taken as representative of the wider population.
However, even accepting this, IWG members found these figures
to be surprisingly high.
2 The social impact of public drug use
This research (Taylor et al., 2006) was carried out in four sites
around the UK known to be associated with public use of drugs
and involved interviews with local people, including council
cleaners, toilet attendants, park keepers, local business employees
and local residents. Interviews were carried out with 100 people,
61 of whom took the researchers on ‘walkabout tours’ of the local
area, pointing out sites where they had seen people using drugs or
found evidence of public drug use. It should be emphasised that
this was a ‘purposive’ sample, selected because their jobs or place
of residence meant that it was particularly likely that they had
witnessed drug use or drug-related litter.
Drug-using locations were identified in alleyways, car parks,
derelict open spaces, neglected property, cafés, toilets, gardens
and stairwells. Half of the participants reported drug dealing, over a
third had seen people injecting and nearly four-fifths had seen at
least one used syringe. Twelve of the 100 participants had
witnessed drug users who had collapsed and/or overdosed.
Participants were annoyed by the drug litter and visible drug use –
particularly if it occurred close to their own homes or where it could
be observed by children.
They were also intimidated by groups of users ‘hanging about’ –
and referred to finding vomit and excrement that they associated
with drug users, some of whom were sleeping rough. Respondents
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generally reacted to these issues with anger, disgust and fear. The
relentlessness of these problems was often viewed as part of a
wider social malaise, which included the sex industry,
homelessness, begging and drug-related crime.
The authors conclude that public drug use and related litter are
associated with significant levels of community concern, reflected
in feelings of reduced safety, public amenity and quality of life.
IWG conclusions
The IWG was surprised by the lack of knowledge about some
aspects of injecting drug use and its associated harms in the UK.
Research had to be commissioned to address fundamental gaps in
our knowledge about injecting in public places. However, the IWG
has been able to draw a number of conclusions from the available
evidence:
 The UK has a substantial population of injecting drug users.
 The UK has the highest number of drug-related deaths in
Europe and has done since 1996.
 There is a high, and probably rising, prevalence of hepatitis C
among drug injectors in the UK. Hepatitis B is also a cause for
concern.
 While considerably lower than in many other countries, HIV
prevalence is increasing again, including one early indication of
a rise among injecting drug users.
 Many users infected with blood-borne viruses are unaware of
their infection.
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 While hepatitis B can be prevented through vaccination, fewer
than half the population of injecting drug users have been
vaccinated.
 Abscesses, cellulitis and other infections are common among
injectors, leading to frequent hospital treatment.
 There is a substantial population of high-risk, homeless,
injecting drug users, mostly based in hostels or rough sleeping.
They inject frequently in public places and are therefore
associated with a lot of public nuisance.
 A significant minority of injectors who live in their own home
also inject in public places.
 People who inject in public places appear to be at high risk of
health problems and overdose.
 Users forced to inject in unhygienic and dangerous public areas
are likely to experience anguish, loss of dignity and low self-
worth.
 Large quantities of used needles and drug-related litter are
dropped in public places and this is a widespread problem
across the UK.
 Discarded syringes, drug-related litter and drug users
congregating on the streets significantly affect the lives of many
people living in areas close to drug markets in the UK.
It would appear, logically, that concentrating injecting drug use
within DCRs could stem some of this extensive damage to
individuals and communities. However, the IWG is clear that
identifying needs potentially addressed by DCRs does not in itself
constitute a conclusive argument for the piloting of DCRs in the
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UK. There would have to be evidence that DCRs are demonstrably
effective in meeting these needs and, moreover, sufficient
indication that they would be more effective than current
interventions. The next chapter considers the international
evidence relating to the effectiveness of DCRs.
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As discussed in the last chapter, it is plausible that DCRs could
have an impact on a range of private and public harms that are
commonly experienced by individuals and communities in the UK.
However, what is the evidence that they have such an impact? At
the time of writing, somewhere in the region of 65 DCRs are
operating in 40 cities in eight countries around the world. Not all of
these facilities have been subjected to a thorough evaluation but
an increasing number of evaluations have been published over the
past ten years.
Evaluation of any project that aims to have a community-level
impact on a clandestine behaviour like injecting drug use is fraught
with problems. It is very hard to know how many injecting drug
users are out there and even harder to contact a representative
sample and interview them. If it is expected that a DCR will have
an impact at a local community level, then local users will need to
be contacted in this way. For this reason, among others, it is much
more difficult to distinguish the impact of a DCR at the community
level than it is to analyse its impact at the individual or project level.
As with all evaluations of community interventions, it can also be
extremely difficult to ascribe changes in behaviour or health to the
project itself. To take an example: if a DCR is associated with a
lower reported level of needle sharing among its users, is this due
to the DCR or another, competing explanation, such as a local
outreach intervention or, alternatively, a wider trend in decreased
sharing among the age cohort using the DCR? Various evaluation
designs have been employed to try to distinguish between
competing explanations but with varying degrees of success. The
most recent evaluations focusing on the Sydney and Vancouver
projects have employed particularly robust designs.
Other issues include the infrequency of some of the possible
outcome variables, such as overdose death, which make it hard to
be sure that an individual DCR has had an effect; and the
4 Are DCRs effective?
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propensity for vulnerable people to answer questions in a way that
they think may please project staff or researchers (particularly
where a high-profile demonstration project has been set up).
Such problems mean that evaluation evidence in this area is
inevitably indicative of whether a project is effective or not rather
than proof of its relative effectiveness. However, when a number of
evaluations appear to be showing similar trends, the evidence
should be regarded as more convincing.
In considering this evidence, the IWG emphasises that these
evaluations relate to DCRs operating in different countries with
different drug-related cultures and problems. Their applicability to
the operation of a DCR in the UK can therefore be questioned.
Ultimately, IWG members conclude that such caveats would only
be addressed through conducting properly evaluated pilots in this
country.
The job of making sense of the evaluation literature has been
greatly aided by the publication of an excellent EMCDDA review on
the subject (Hedrich, 2004), which has been drawn on extensively
in our work. This chapter is divided into five sections. The first four
address the following key questions relating to effectiveness:
 To what extent do DCRs reach their target group?
 What is their impact on health?
 What is their impact on local communities?
 How do they compare to other interventions and are they cost-
effective?
The last section brings together the evidence of need from the last
chapter with this evidence relating to effectiveness and reaches
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conclusions about the extent to which the UK might benefit from
the introduction of DCRs.
Reaching the target group
1 User characteristics
The EMCDDA review states that the target populations of DCRs
are:
typically defined as high-risk problem drug users, especially
regular or long-term users of heroin and cocaine, drug
injectors, drug-using sex workers, street users and other
marginalised, often not in treatment, groups.
(Hedrich, 2004, p. 24)
As the review goes on to point out, the socially marginalised nature
of this target group means that restrictive rules and regulations are
not likely to be attractive. However, if DCRs are to operate within
parameters that have official sanction and ensure the safety of
their users, properly observed rules are a necessity. This is a
conundrum that affects DCRs’ ability to attract the most socially
excluded users.
Another important issue affecting targeting is the potential for
DCRs to introduce users to injecting drug use. It is possible that
the existence of a safe environment for drug injecting might push
someone hovering on the brink of injecting heroin for the first time
to go over the edge. DCRs generally try to restrict their clientele to
experienced drug users but this is actually very hard to ensure in
practice. Age restrictions are usually put in place as one means of
deterring this potential ‘net widening’ effect but, of course, different
people start using drugs at different stages of their lives.
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Turning to the research evidence, 15 ‘key studies’ were drawn on
by the EMCDDA review in its consideration of the target groups of
DCRs. The typical DCR user is a male over 30 years of age, who
is a frequent user of heroin and/or cocaine and has been injecting
for at least ten years. A substantial proportion of a typical DCR’s
users will have been injecting in public places prior to using the
DCR (for example, 39 per cent of the Sydney MSIC users had
injected in a public place within the last month). There are, of
course, exceptions to this picture, perhaps most notably those
DCRs that are set up specifically to attract drug-using sex workers.
The first evaluation report of the DCR set up in Vancouver (Insite)
was published after the EMCDDA review and showed that a similar
profile of users were accessing the facility (British Columbia Centre
for Excellence in HIV/AIDS, 2004). Seventy per cent of users were
male and the mean age of the group as a whole was 39.
A significant proportion of DCR users are homeless but the actual
percentage varies greatly according to the definition of
homelessness and the DCR’s location and purpose. Sixty per cent
of the users in a DCR in Barcelona were defined as homeless,
reflecting this DCR’s targeting of marginalised users. By
comparison, a recent survey of all German consumption rooms
found that 5 per cent lived on the street (Hedrich, 2004). Twenty-
two per cent of the Vancouver sample were defined as of no fixed
abode or living on the street (British Columbia Centre for
Excellence in HIV/AIDS, 2004). The extent to which a local DCR
has been able to attract a substantial proportion of local, homeless
drug users has not been addressed in the literature. However,
some of the Dutch projects specifically target small groups of local,
homeless individuals who are known to be causing significant
amounts of public nuisance and, from IWG visits to such projects,
they appear to be successful in achieving this aim.
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Although, as outlined above, DCRs usually try to exclude
experimental or intermittent injectors, studies in Switzerland have
revealed that a small percentage (0.5–4.5 per cent) of DCR users
report that they had their first injection in a DCR (Hedrich, 2004).
This demonstrates that, so long as a DCR is accessible to a broad
range of drug users, it is inevitable that a small number will first
inject within the premises. Whether or not, in the absence of a
DCR, such people would have injected a drug in any case is open
to conjecture.
One of the main and, in the view of the IWG, completely
understandable community concerns surrounding the setting up of a
DCR is that it will attract even more users to the area – the
‘honeypot’ effect. Research has been conducted on the proportion of
service users who live locally and has found that between 63 and 93
per cent report living in the local area, however defined (Hedrich,
2004). The number of people that are attracted to a DCR from
outside the immediate area is likely to depend on several factors,
including the DCR’s policy; the local policing policy; the number of
other DCRs in the locality; the location and nature of drug markets;
and the availability of needle exchange, treatment and hostel
facilities for users. These issues are considered in more detail in the
later section on the impact of DCRs on local communities.
The potential for DCRs to refer users who have never previously
addressed their drug use problem on to treatment agencies was
identified in the previous chapter. The evidence on DCR attendees
suggests that the potential does exist, with between 15 and 50 per
cent never having been in treatment before (Hedrich, 2004). DCRs’
actual effectiveness in referring users on to treatment is considered
below under the section on health impact.
Finally, DCR users are usually able to gain access to a range of
needle and syringe exchange, medical and social care, counselling
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and housing services through co-operation between DCRs and
other services.
2 Utilisation and coverage
Heroin and cocaine are the main drugs used, sometimes in
combination, and the main mode of use is injecting. However, in
the Netherlands, where the majority of heroin users inhale drugs,
services have separate areas for those who inhale and those who
inject. DCRs designated for the inhalation of drugs have recently
been set up in Switzerland and Germany in order to promote less
risky modes of drug use.
DCRs vary enormously in the extent of their use, depending on the
number of spaces for users, the size of the local user population
and the eligibility criteria. At one end of the scale, a weekly average
of 50 supervised consumptions has been reported; at the other, the
Vancouver project reported a weekly average of over 3,000
(Hedrich, 2004; British Columbia Centre for Excellence in HIV/
AIDS, 2004). Studies in Germany and Switzerland show that many
people use services on an average of five times a week. In the
Netherlands, where projects usually focus on comparatively small
groups of homeless users, average usage rates per person can be
as high as six days per week (Hedrich, 2004). The Vancouver
project was used by 3,036 individuals in a six-month period, during
which 79,962 injections took place. The average individual usage
rate was 11 visits per month (British Columbia Centre for
Excellence in HIV/AIDS, 2004).
The location of a DCR is a vital consideration. In one study of
German service users, it was found that, in addition to the
provision of safe and hygienic conditions, one of the main reasons
given by users for utilising a particular DCR was its proximity to a
drug market. In another study of three DCRs in Frankfurt, it was
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found that the extent of their use was related to their distance from
the local drug market. Similar results have been found in Hamburg,
where there was a policy decision to try to move users out of the
city centre by relocating drug services, including DCRs, outside the
centre. The relocated DCRs were used very little (Hedrich, 2004).
Opening times vary from many being open eight or nine hours a
day to some which are open 24 hours a day. Extending opening
hours at night can lead to more supervised injections, more users
and different kinds of users. The extent to which services can
stretch to cover nights and weekends is likely to be crucial in the
degree to which they ‘capture’ a significant amount of local
injecting.
On the question of the proportion of injecting episodes in public
places that can be ‘captured’ by DCRs, Hedrich (2004) provides
interesting case histories of the DCRs set up in Frankfurt, Hamburg
and Zurich. In the early 1990s, each of these cities was faced by
open drug markets and public drug use. In each case, a number of
DCRs had to be developed in order to have a significant impact on
public injecting: five in Zurich, four in Frankfurt and eight in
Hamburg. This makes an interesting contrast to the situation in
Sydney and Vancouver, where drug users and drug markets have
been concentrated in quite small areas of the city. Single DCRs
with very high turnovers appear to have been able to have an
impact more readily in these circumstances.
3 Conclusions on reaching the target group
The research evidence from DCRs abroad suggests that they are
largely successful in attracting considerable numbers of long-term
users, many of whom are socially excluded and out of contact with
treatment services and a significant proportion of whom will have
never had any contact.
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DCRs have generally been set up for local users with little
evidence of ‘honeypot’ effects. Those who use DCRs regularly tend
to be locals. DCRs are rarely used by novice injectors.
While this report focuses mainly on injecting drug use, a number of
drug consumption rooms in Europe also provide a service for those
wishing to inhale their drugs. It is at least logically possible that
DCRs which do not offer space for inhalation might thereby
encourage drug users into injecting – or, at least, reinforce this
behaviour.
The success of DCRs in attracting users depends crucially on their
location with proximity to drug markets being the key factor.
Maintaining long opening hours is also vitally important.
Finally, there is evidence that, possibly where drug markets and
public drug use are more diffuse, multiple DCRs may be needed in
order to ‘capture’ a significant proportion of public injecting.
Impact on health
If a DCR is to have an impact on health, the literature suggests that
it needs to provide four essential services:
1 ensure relatively safe and hygienic injecting in the facility
2 provide personalised advice and information on safe injecting
practice
3 recognise and respond to emergencies
4 provide access to a range of other on-site and off-site
interventions and support.
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If these services are successfully delivered to a sufficient number
of people, it is likely that the DCR can then have an impact on a
number of health-related outcomes:
1 overdose
2 transmission of blood-borne viruses
3 other health problems, such as abscesses
4 rates of drug use.
This section is therefore divided into two: the first addressing the
four services provided by DCRs, the second the four outcomes.
Service provision
1 Ensuring relatively safe and hygienic injecting
The many problems associated with the failure to inject safely and
hygienically have been alluded to in the previous chapter and a
central aim of DCRs is therefore to provide clean injecting
equipment, a clean environment in which to inject, a clear code of
conduct and some clinical supervision of the injecting process.
House rules and regulations, such as the prohibition of the sharing
of injecting equipment and injecting in the neck, are instituted and
‘policed’ through supervision of the injecting process. However, do
these procedures work? Are DCRs successful in ensuring safe and
hygienic injecting within their walls? There appears to be an
assumption in the literature that all of the injections that take place
in a DCR take place in a safe and hygienic manner (Hunt, 2006b).
Thus it is assumed that, given the existence of clear policies to
ensure this, all those injecting in DCRs do so safely. While this is,
indeed, likely to be the case in the majority of DCRs, particularly
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where injection is closely supervised, it is still possible that some
unsafe injecting practices do take place in DCRs with lower levels
of supervision. The IWG is of the opinion that future evaluations of
DCRs should include more observation of their operation, including
the process of supervision and the enforcement of house rules.
This should be one focus of any independent evaluation.
Nevertheless, there can be no doubt that, in well-run DCRs, the
large majority of injection episodes take place in relative safety and
this is borne out by IWG members’ visits to DCRs in the
Netherlands, Germany, Switzerland, Canada and Australia. The
degree of benefit will depend on the nature of the injecting
episodes that would otherwise have taken place: if a homeless
person injecting in a DCR would otherwise be injecting with
someone else’s syringe in a public toilet, using toilet water to
dissolve the drug, then the health dividends are much greater than
for a DCR client who would otherwise be injecting safely in their
own home. It is clearly impossible to know with any certainty the
type of injecting episodes that have been prevented when users
inject in a DCR: users themselves may find it difficult to state how
and where they would have injected had they not been visiting a
DCR. Nevertheless, the evaluation of the Sydney MSIC included
asking the 3,782 clients where they would have injected if there
was no DCR (MSIC Evaluation Committee, 2003). Forty-two per
cent reported that their next injection would have been in a public
place. As we have seen, injecting in public places is associated
with greater risks than injecting in other locations. Moreover, DCRs
appear to be generally successful in attracting homeless users and
other people who regularly inject in public places. It seems likely,
therefore, that the impact in terms of preventing unsafe and
unclean injecting episodes is great. Furthermore, it should certainly
not be assumed that this preventive ‘dividend’ applies only to those
who inject in public places. While Taylor et al.’s (2004) video-based
research on 48 injecting events confirmed the fact that injecting
indoors was associated with fewer risks than injecting outdoors,
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there were still numerous instances of risky injecting practices in
the flats where the majority of the injections took place. There may
therefore be a preventive dividend for the majority of injection
episodes that take place in a DCR.
Preventing individual instances of dangerous injecting is a
somewhat limited goal. It is highly unlikely that an individual user
will always inject their drugs within DCRs. While for some health
aspects, such as damage to veins or the development of
abscesses, capturing only a proportion of injecting episodes will
still bring significant benefits, for other health aspects, such as
hepatitis C, preventing contraction of the virus within the DCR may
appear of limited value if all it takes is one instance of sharing
injecting (or drug preparation) equipment outside the DCR to lead
to infection. This begs the question of the extent to which DCRs
can influence injecting practice beyond their walls. This is
addressed in the next section.
2 The provision of advice
DCRs provide a unique opportunity to observe an individual’s
injecting practice and offer advice. By comparison to a syringe
exchange project, for example, there is a much greater potential to
establish a detailed knowledge of the particular habits and dangers
that users have built up as part of their regular injecting practice,
simply by directly observing them. This then gives the potential for
tailored advice designed to reduce the risks associated with their
injecting. DCRs also offer the opportunity to provide more general
health-related information and sterile injecting equipment for users
to take off the premises. DCRs therefore have much potential in
this regard but is this potential realised?
As Hunt (2006b) points out, there is a lack of information in the
literature on the extent to which DCRs provide such advice to
users. However, some useful information comes from the
44
Report of the IWG on Drug Consumption Rooms
evaluation of the Sydney MSIC (MSIC Evaluation Committee,
2003). In nearly 14 per cent of the visits to the MSIC, advice on
injecting and/or vein care appears to have been given to the user:
a total of 7,732 occasions over an 18-month period. Project
workers referred to this work in their interviews with the evaluation
team. Despite most of the clients being experienced injectors, staff
referred to their ‘amazement at their [poor] injecting technique’ and
the need to ‘de-ritualise some of the entrenched rituals of injecting’
(MSIC Evaluation Committee, 2003, p. 30). Staff agreed that
injecting techniques had generally improved as a result of their
interventions, describing ‘a huge impact from both a blood-borne
virus point and a potential death issue … [There’s] been an
increase in hand washing definitely … also less bruising, scars and
abscesses’ (MSIC Evaluation Committee, 2003, p. 30). Several
members of staff thought that this input was one of the main
benefits conferred by the MSIC.
While evaluations seem to have largely failed to measure the
nature and extent of advice given to users, many have addressed
the question of whether users have changed their behaviour as a
consequence of attending DCRs. However, there are significant
methodological problems here and studies have taken various
approaches to the question (Hedrich, 2004). Some have followed
up clients over time to see how their behaviour changes. However,
without comparison samples, it is hard to distinguish between
changes that are a consequence of attending a DCR and ‘natural’
changes in behaviour that would have occurred in any case. Other
studies have compared DCR users with other samples of users
who do not use DCRs. The value of this approach is limited by the
extent to which such samples are identical in all aspects other than
their attendance/non-attendance at a DCR. Given the sensitivity of
many of these health measures to factors such as homelessness,
age and drug-use experience, it is hard to be sure of comparability.
Other studies have simply asked users whether, in retrospect, they
ascribe any changes in behaviour to the DCR. Here, the
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researcher is dependent on the user’s memory of their earlier use,
rather than having a baseline measure, as well as having no
means of attributing the change specifically to the DCR.
Bearing in mind such shortcomings, what does the evaluation
evidence show? Earlier studies have indicated an increased
knowledge and awareness of risk and a decrease in needle and
syringe sharing among DCR clients (Hedrich, 2004). The
methodological problems associated with these evaluations have
precluded a stronger conclusion. However, the evaluation of the
Vancouver project has employed a more sophisticated approach,
drawing on previous epidemiological surveys of injecting drug
users, and has shown that the introduction of the DCR was
associated with reduced syringe sharing among those attending
the project (Kerr et al., 2005; Wood et al., 2005).
There remains a real need for better evaluation in this area: both
observation and other qualitative work on the provision of advice to
injectors and quantitative designs focusing on behaviour change,
which need to include both a longitudinal and comparative
element.
3 Recognising and responding to emergencies
DCRs vary in the level of medical supervision that they provide.
The MSIC in Sydney has nursing staff and/or a doctor present at
all times, allowing immediate and early response to overdose
incidents (MSIC Evaluation Committee, 2003). It also has a fully
equipped emergency room and staff on site able to administer
naloxone.1 While most other DCRs have doctors and/or nurses
working within them, there is variation in their ability to provide on-
site intervention in emergencies and, in some cases, a greater
reliance on ambulance call-outs to treat overdose cases (Hedrich,
2004). These issues are dealt with in the consideration of
outcomes.
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4 Other interventions and support
Aside from the functions already described, international surveys
have shown a standard DCR service to provide needle and syringe
exchange programmes, basic medical care, counselling and
referral to a range of off-site services (Hedrich, 2004). As stated
above, most DCRs have doctors on site either part-time or full-time
and where they do not, most have nursing staff on site. Some
services also provide food and drink, showers and laundry
services. A small number of DCRs form part of integrated services
which include hostel accommodation on the same site.
Medical consultation, wound care services and counselling are
provided in between 5 and 10 per cent of visits to DCRs (Hedrich,
2004). The Sydney MSIC provided a total of 13,696 services (in
addition to supervision of injection) to 2,186 users over an 18-
month period. After injecting and vein care advice, the most
common service provided was ‘general counselling’ but there
followed a long list of the provision of other information, medical
and social services (MSIC Evaluation Committee, 2003).
With regard to referrals to other services, rates vary significantly
across DCRs, from 9 to 54 per cent (although direct comparison is
difficult: Hedrich, 2004). The Sydney MSIC referred 15 per cent of
its users to other agencies, many on more than one occasion.
Fifty-five per cent of the 1,385 referrals were verbal; 45 per cent
written. Forty-three per cent of all referrals were for drug treatment;
32 per cent for health care; and 25 per cent for social welfare. Of
course, the act of referring a person to another agency does not
mean that that person will show up and receive help. ‘Referral
cards’ were sent out with the written referrals and over one in five
of these were returned as confirmation of the MSIC client’s
attendance. With regard to treatment, 49 of the 300 written
referrals (16 per cent) resulted in a user attending the agency to
which they were referred. Methadone maintenance had the highest
rate of successful referral (MSIC Evaluation Committee, 2003).
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The Vancouver project made 262 referrals to addiction counselling
services over a six-month period, with 78 referrals to withdrawal
management programmes (British Columbia Centre for Excellence
in HIV/AIDS, 2004).
It does not seem particularly impressive that of the 3,782
registered MSIC clients over the 18-month period, 49 (or 1.3 per
cent) were known to have attended a drug treatment service.
However, as the evaluators point out, these figures are likely to
underestimate the rate of successful referral (MSIC Evaluation
Committee, 2003). There was no mechanism for finding out the
success or otherwise of verbal referrals. Moreover, referral cards
may not have been handed over to agencies by users and may not
have been sent back by agencies. The inevitably ‘hit and miss’
nature of referring users elsewhere argues for the maximum
provision of services on site as well as the need for integrated
rather than specialised DCRs (see Chapter 6).
In conclusion on service provision, it seems highly likely that DCRs
provide much safer and cleaner injecting environments for the
majority of the injecting episodes that take place in them. They also
provide a range of additional services, including advice on safer
injecting. There is the suggestion that some of this advice may
influence injecting practice outside the DCR, including the sharing
of injecting equipment. Other useful services are provided within
DCRs, including medical and social services. Many referrals are
made to other agencies but, unsurprisingly, a low percentage
appears to be taken up. The next section examines the impact of
DCRs on the key outcomes.
Outcomes
1 Overdose
Concern about drug-related deaths has been an important spur to
the development of DCRs in many of the countries hosting them.
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By providing safety-related rules, supervision of the injecting
process and medically trained staff, it is hoped that overdose
deaths can be prevented. Non-fatal overdose is also a significant
issue, frequently associated with serious health implications for
users and drawing on ambulance and hospital resources. DCRs
provide the potential to intervene at an early stage in the overdose
process and thus avert the need for hospitalisation.
The large majority of reported emergencies within DCRs are
overdoses relating to heroin, but there are also small numbers of
cocaine overdoses and epileptic seizures (Hedrich, 2004). The
most frequent way in which heroin overdose causes immediate
death is through respiratory depression, often in combination with
other drugs, particularly alcohol (ACMD, 2000). DCRs can
therefore prevent deaths through aiding users’ breathing and
administering naloxone.
As Hunt (2006b) points out, there are a number of stages at which
DCRs could have an impact on overdose events:
 DCRs prevent emergencies from occurring in the first place.
 Emergencies are managed earlier than would otherwise have
occurred.
 Emergencies are managed with lower-intensity interventions
than would otherwise have occurred.
 DCRs reduce morbidity and mortality from emergencies.
Evaluating a DCR’s preventive role in these respects is difficult:
how does one know that, without an intervention, the emergency
would not have escalated?
There is a considerable amount of evidence on the incidence of
emergencies within DCRs. The rate of emergencies seems to vary
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very widely: from 0.5 to 7 emergencies per 1,000 supervised
injections (Hedrich, 2004).2 Reasons for this wide variation are
likely to include differences in the nature of the target group and
different definitions of what constitutes an emergency requiring
intervention. However, it is clear that dangerous situations that
require intervention arise frequently in DCRs (as they do in any
drug-injecting context). The Sydney MSIC had the highest rate of
emergencies (seven per 1,000 injections) and 329 heroin-related
overdoses were managed by the staff over the 18-month
evaluation period.
Paradoxically, these high rates of non-fatal emergencies point to
the efficacy of projects in preventing the more serious overdose
events that might have occurred were these emergencies to have
taken place outside DCRs.
The proportion of emergencies dealt with by DCR staff will depend
on the extent to which medically trained staff and the necessary
equipment are present (Hedrich, 2004). Ninety-eight per cent of the
emergencies at the Sydney MSIC, which has a doctor or nurse
present at all times, were dealt with by the staff. DCRs which do not
have a doctor present have much higher ambulance attendance
levels: up to 70 per cent of emergencies (Hedrich, 2004).
Following ambulance call-out, some users are admitted to hospital.
The proportion of emergencies resulting in hospitalisation varies
between 2 and 8 per cent for the three studies addressing the
issue in the EMCDDA review (Hedrich, 2004).
It is therefore clear from the foregoing that not only are
emergencies a fairly frequent event in DCRs but that these are
responded to. How effective are these responses? The most
obvious measure is the one where information is readily available:
the number of overdose deaths. There has only been one
reported death in a DCR since the first DCR was introduced in
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1986: in December 2002 a drug user died from anaphylaxis (a
severe, whole-body allergic reaction) in a German consumption
room (Hedrich, 2004). Injecting drug use is a very dangerous
activity and millions of injections will have taken place within DCRs
over the 20 years since their inception. As Hunt (2006b) points out,
this statistic offers powerful evidence of the safety of DCRs.
While it is therefore clear that DCRs largely prevent overdoses
occurring while clients are injecting within them, a more testing
question is whether a DCR can be shown to have an impact at a
community level. However, the impact of a DCR in this respect will
always be limited by the following factors (MSIC Evaluation
Committee, 2003):
 A DCR can only prevent deaths during its hours of operation.
 A proportion of the local users will not use the DCR.
 Those that do use the DCR will inject elsewhere some of the
time.
Nevertheless such analyses have been attempted in Sydney and
Germany. The evaluation of the Sydney MSIC included a
sophisticated set of analyses of the impact of the DCR on drug-
related deaths. However, the community-level measurement of
impact was undermined by the rapid decrease in the availability of
heroin which occurred shortly before the MSIC opened (Bush et
al., 2004). This was associated with a rapid decrease in overdose
deaths and made the measurement of the impact of the MSIC at
community level impossible. Nevertheless, using the proportion of
overdose ambulance call-outs in New South Wales that end in the
death of the user and applying this figure to the 81 more serious
overdose cases in the DCR (which were treated with naloxone), a
conservative estimate was made of four lives saved per annum.
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Evidence of community-level impact is provided by a ‘time series’
analysis of the impact of DCRs on overdose death rates in four
German cities (Poschadel et al., 2003, referenced in Hedrich,
2004). This research concluded that DCRs were ‘statistically
significantly related to the reduction of drug-related deaths’
(Poschadel et al., 2003, referenced in Hedrich, 2004, p. 52).
Another analysis of German data, which applied estimated
overdose mortality rates to the number of supervised
consumptions, found that ten deaths per year were prevented by
the German DCRs (Hedrich, 2004).
In conclusion on the prevention of overdose deaths, it is
unfortunate in the context of the Sydney MSIC that this, the best
test of the impact of a DCR hitherto, was undermined by dramatic
changes in the availability of heroin. Other analyses are inevitably
complex and hedged by caveats. Nevertheless, it is unarguably the
case that DCRs save lives. How many is less clear.
The research base is unable to say anything concrete about the
extent to which DCRs might prevent emergencies occurring in the
first place – or intervene earlier to prevent the escalation of an
overdose event (Hunt, 2006b). One issue here is that DCRs may
prevent overdoses occurring on site by excluding from the facility
people who are already intoxicated. Intoxication with alcohol is an
important risk factor for heroin overdose (ACMD, 2000). It may be
possible for DCR staff to persuade users to come back and inject
when they are sober. However, it is likely that such users may
simply go on to use their drugs elsewhere, in which case, should
they overdose outside the DCR, these could hardly be regarded as
overdoses ‘prevented’. Relevant here is the fact that some DCRs
intervene in overdose cases occurring locally on the streets. Where
intoxicated users are excluded, it may be possible to ‘keep tabs’ on
them outside the facility. Users at DCRs may also be asked what
drugs they are injecting and may be discouraged from using
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certain combinations of drugs (or prevented from using them on
the premises). This may deter users from more lethal injections.
Finally, DCRs offer the opportunity for users to take their time in
measuring their dose, rather than rushing their injections in a
poorly lit environment. Such possibilities require evaluation.
Preventing overdose incidents from escalating seems a very
important goal and further detailed research here would be very
useful. However, as Hunt (2006b) has pointed out, there is also the
theoretical possibility that DCRs might contribute to emergencies
by making users more inclined to risk using drugs that they know
will be dangerous because they believe they will be safe within a
DCR. Further careful evaluation of these issues is needed.
2 Transmission of blood-borne viruses
It is much easier to examine the impact of DCRs on self-reported
needle and syringe sharing than it is to examine their impact on the
transmission of blood-borne viruses. The Sydney MSIC evaluation
found no impact on viral transmission, although this study was
confounded by the Australian heroin drought, which had a marked
effect on the entire drug scene throughout the duration of the
evaluation.
The problems involved in establishing whether or not a project has
had an impact on the transmission of viruses are considerable. The
low incidence of blood-borne viruses means that it is very difficult
to measure impact (MSIC Evaluation Committee, 2003) and the
problem may therefore be primarily one of evaluation rather than
programme failure: as the EMCDDA review concludes, ‘it is likely
that the direct and personalised safer use education in the setting
of supervised consumption rooms contributes to a reduced risk of
transmission of infectious diseases even outside the room’
(Hedrich, 2004, p. 54). But this is very hard to show beyond doubt.
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3 Other health problems, such as abscesses
As described above, DCRs frequently offer medical services on
site and also refer users to off-site medical services. Given the
large number of visits to DCRs, this can mean large numbers of
treatments. The three Zurich consumption rooms delivered an
annual average of 3,122 wound care services; for the Sydney
MSIC, this figure was 847; and the DCR in Madrid provided
medical services on an average of 3,902 occasions per year. The
Sydney MSIC also referred clients to off-site health care services
on 439 occasions over an 18-month period and health care
referrals had the highest uptake rate.
As Hunt points out, ‘given that many people who use DCRs are
highly marginalized and with poor access to healthcare services,
this evidence strongly suggests that DCRs fulfil an important
function in providing primary health care … interventions to a very
needy population’ (Hunt, 2006b, p. 25).
4 Impact on drug use
As has been shown, DCRs provide psychosocial counselling on
site and refer users to a range of agencies including treatment
services. It could therefore be anticipated that DCRs might have a
beneficial impact on drug use, both through referral to treatment
and through impacting on some of the multiple social problems
experienced by socially excluded users. Alternatively, it might be
thought that the presence of a safe place to inject drugs might
increase drug use.
A number of studies have examined this question and, as summed
up by Hunt (2005b), most find a minority of people (up to 16 per
cent) who report increased frequency of drug use since using the
DCR and others who report decreased use (up to 22 per cent).
With any population of drug users some will be increasing and
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others will be decreasing their use and it seems likely that these
findings may simply reflect the natural flux in patterns of use. A
recent study of drug users in Vancouver found that the opening of
the DCR was not associated with any measurable negative
changes in injecting drug use. The only significant change was a
reduction in the initiation of binge drug use following the
introduction of the DCR (Kerr et al., 2006).
In summary on health outcomes, it seems highly likely that DCRs
prevent overdose deaths and allow earlier intervention in a
substantial number of potentially fatal overdoses. The IWG
attaches considerable importance to the following fact: over the
years, DCRs have supervised millions of injections of
potentially dangerous illicit drugs, frequently involving users
with serious health problems, and yet only one person has
died. It is difficult to measure the number of lives saved by an
individual DCR and even harder to measure the impact of DCRs
on drug-related deaths at the community level. However, the
methodological problems involved here should not detract from
DCRs’ considerable success in preventing overdose.
DCRs are clearly successful in providing on-site medical care and
referring users to off-site medical services. They are also likely to
be having some impact on blood-borne viruses but this has not yet
been shown. There is no convincing evidence that they impact on
levels of drug use in either direction.
Impact on local communities
A central aim of DCRs is to reduce the amount of injecting that
occurs in public places and to reduce the amount of associated,
discarded injecting paraphernalia. However, as the EMCDDA
(2005) review points out, plans to set up a DCR have often been
met by resistance from local residents and businesses who fear
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that it will attract more users to the area – and associated crime
and drug dealing. What is the evidence on either side?
Reduction in public injecting
A range of evidence points to DCRs resulting in a decrease in
injecting in public places (Hedrich, 2004). Interviews with DCR
users in Rotterdam and Hamburg have shown that users report
reduced rates of public drug use as a result of their attendance at
the DCR. However, while DCR users may reduce their level of
public injecting, many still continue to use in public. Research in
Hamburg, which found that 37 per cent of respondents had used in
public during the past 24 hours, identified withdrawal symptoms, in
conjunction with long waiting times for access to the injecting room,
distance from place of purchase and limited opening hours as the
main reasons for so doing.
More convincing evidence of impact comes from Switzerland,
where users of low-threshold drug services have been regularly
surveyed in order to evaluate the Swiss AIDS prevention strategy
(Hedrich, 2004). Survey data were collected from users in Biel and
Geneva, before and after the introduction of DCRs. Before the
introduction, 21 per cent and 18 per cent of users in Biel and
Geneva respectively reported using mainly in public places. After
the introduction of DCRs, these figures had fallen to a single
individual in Biel and 10 per cent of users in Geneva. Forty-nine
per cent of the users in Biel and 29 per cent of the users in Geneva
referred to DCRs as their most frequent location for drug use.
The strongest evidence comes from the evaluation of the
Vancouver project which involved an array of observational
measures, including people seen injecting in public places.
Comparing the six-week period before the establishment of the
DCR with the 12-month period afterwards, there was a statistically
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significant reduction in the number of users seen injecting in public
places: from a daily average of 4.4 to a daily average of 2.4. This
relationship held true when rainfall (which was expected to be
associated with lower rates of outdoor drug use) and police
presence were taken into account (Wood et al., 2004).
Reduction in discarded syringes and drug-related litter
Until recently, research on discarded syringes and needles has
proved largely equivocal. While, following the introduction of the
DCR, a drop in discarded syringes was recorded in the area
around the Sydney MSIC, it was unclear whether this could be
attributed to the DCR or the decline in heroin availability. A slight
increase in discarded syringes was recorded following the setting
up of the DCR in Biel, despite a high return rate for needles and
syringes given out. Researchers suggested that this might be due
to an increase in cocaine use (and the associated increase in the
frequency of injecting). Surveys of residents living near the Dutch
DCR in Venlo showed a reduction in discarded syringes following
implementation (Hedrich, 2004).
Again, the strongest evidence of the impact of DCRs on drug-
related litter comes from the Vancouver study. Whereas a daily
average of 11.5 discarded syringes were found before the opening
of the DCR, this average figure dropped to 5.3 after its opening.
Injection-related litter (syringe wrappers, syringe caps, sterile water
containers and ‘cookers’) showed a drop in the average daily count
from 601.7 to 305.3. Both these differences were statistically
significant and independent of law enforcement activity and rainfall
patterns.
Public nuisance: ‘honeypot’ effects, crime and dealing
As has already been described, research has found that the large
majority of DCR users live locally, although the proportion of local
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users will vary according to a number of factors: the DCR’s policy;
the local policing policy; the number of other DCRs in the locality;
the location and nature of drug markets; and the availability of
needle exchange, treatment and hostel facilities for users. As
DCRs tend to be located near drug markets, their clientele is likely
to reflect the profiles of users buying drugs in those local markets.
In the case of a DCR where there is a large, local population of
drug users (such as Vancouver), it should prove relatively
straightforward to ensure, and to demonstrate, that the DCR has
mainly provided a service to the local population of users.
However, if a DCR is located close to a city drug market which is
used by people migrating in from a wide area in order to buy their
drugs (such as Frankfurt), a greater proportion of ‘non-local’ users
is likely to be recorded. This does not mean that the DCR has
necessarily attracted new users who otherwise would not have
been in the area: many would have come in to buy their drugs in
any case. In such circumstances, more sophisticated ‘before and
after’ designs need to be used to evaluate the extent to which a
DCR has acted as a magnet for users over and above the local
drug market.
In considering the extent to which DCRs might act as a magnet to
users who would otherwise not have been in the area, it is useful to
consider the mindset of the average user. As the users who gave
evidence to the IWG pointed out, an addicted injecting heroin user
is likely to be primarily driven by the need to obtain their drugs. If
they have the money, their first port of call will be a dealer. If there
is somewhere nearby where they can safely use their drug (and
obtain a clean syringe), then this is likely to be their next step. If
they need to go any distance to reach such a place, their need to
inject their drug is likely to lead to them using somewhere else
(often a public area nearby). Consistent with this picture is the
finding from a number of studies that DCRs located any distance
from drug markets attract very few users (Hedrich, 2004). Thus,
there appears little reason to assume that a DCR will act as a
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magnet for users, drawing them in from other areas, so long as
drug dealing is excluded from the premises and the immediate
surrounding area. If a new drug market were to flourish around a
DCR, this would be likely to draw in users who would otherwise
have bought their drugs elsewhere.
However, there are two potential problems with this analysis. First,
at the micro level, even if a new DCR does not lead to an
increased number of users coming into an area from outside, it is
likely to lead to changes in the flow of local users through the
streets surrounding a DCR. The increased passage of users
between the local market and DCR would mean greater exposure
to drug users for some residents and businesses. Others
(particularly those previously affected by injecting in public places)
are likely to benefit. One way to prevent such problems is to set up
DCRs within or alongside other drug services, such as syringe
exchanges. In this situation, services are already attracting users
and there is unlikely to be a significant net increase in local users.
Second, this analysis depends on market stability. Where markets
are unstable, for whatever reason, users and dealers may shift
location. This can lead to declining numbers using a DCR. These
potential problems emphasise the need to undertake detailed
monitoring and ‘scoping’ of local drug markets before siting a DCR
and the need for good interagency working to ensure that problems
can be responded to.
Some of these issues are borne out by the history of the first DCR
in Hanover (Hedrich, 2004). This DCR was set up in 1997, one
kilometre from the city centre drug market and ‘open drug scene’.
Three months into its operation the weekly number of injections
had reached 300 but this figure fell sharply to 130 in the fifth
month. Among the users’ explanations for this fall was the distance
from the drug market and police interventions on the route to the
service. Changes in police practice were agreed (as well as some
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amendments to procedures in the DCR) and this was followed by a
return to the earlier levels of usage. At this point, there was no
dealing occurring outside the facility and very little trouble between
users and residents or the police. However, in subsequent years
the police put increasing pressure on the local drug market, with
the result that the area in front of the DCR became a new meeting
place for users. By 2001, average weekly use had reached 800
and the relocated drug scene led to much more nuisance for
people living in the local area.
There has been a strong focus on general drug-related nuisance in
the Netherlands, where DCRs have been set up largely in
response to such community concerns. Research has shown a
positive impact, with the five studies comparing nuisance levels
before and after implementation finding lower levels of reported
nuisance after the DCRs were set up (Hedrich, 2004).
A study of all the consumption rooms operating in Germany found
that the level of reported nuisance problems was related to the
quality of co-operation between the police and drug services:
where there was agreement about the need for DCRs and a
shared understanding of their public health and public order
functions, fewer public order problems occurred. In others such as
Hanover, where this did not appear to be the case, problems did
arise.
Recent evidence on the overall impact of a DCR on the local
community comes from the evaluation of the Sydney MSIC, which
included surveys of local public opinion. A recently published paper
has compared the views of local people and businesses seven
months before the DCR opened with those reported 17 months
after it had opened. Results show that support for the MSIC
increased significantly over this period and that residents’
perceptions that DCRs attract drug users or make law enforcement
difficult decreased significantly (Thein et al., 2005).
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One aspect of public nuisance not addressed in the literature is
that of overdoses. Overdoses that take place in public places can
be very upsetting for those directly and indirectly involved. As
referenced in the last chapter, 12 of the sample of 100 in the
research carried out for the IWG on the community impact of public
injecting had witnessed incidents involving overdose or the
collapse of users (Taylor et al., 2006). Overdose deaths (whether
or not they occur in public areas) are likely to become widely
known about and can have a significant impact on the image a
community has of itself. Thus, to the extent that DCRs prevent
overdose incidents taking place, they may contribute to a
community’s sense of well-being. This issue is worthy of future
research attention.
On the specific issues of crime and drug dealing, various studies
have drawn on local police data to assess whether there is any
impact of DCRs on acquisitive crime, including robbery. No impact
on crime levels (in either direction) has been found. As DCRs do
not seek to replace illicit drugs with prescribed drugs, this approach
does not break the need for dependent drug users to commit crime
in order to finance their drug use. However, ‘integrated’ DCRs,
which directly or indirectly provide access to a range of other
services such as treatment, housing and employment, may lead to
a reduction in the need for illicit drugs and associated crime in
individual cases.
A number of studies have reported some dealing in the immediate
vicinity of DCRs. Because of the proximity of most DCRs to drug
markets, it is hard to differentiate between dealing that would have
occurred in the area in any case and dealing specifically
associated with DCR users. Such problems can be addressed
through DCR policies which prohibit dealing and ‘loitering’ near the
premises and police action and surveillance to prevent users
gathering in the immediate areas surrounding drug consumption
rooms (Hedrich, 2004).
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Conclusion on public harms
There is good evidence that DCRs can lead to a reduction in
injecting in public places and some evidence that they can lead to
a reduction in discarded syringes and drug-related litter. Crucial
issues here are accessibility and opening times: the closer DCRs
are to drug markets and the longer they are open, the greater their
likely impact on public injecting.
Fears that large numbers of users might be attracted to DCRs who
would not otherwise be in the area appear to be misplaced: the
large majority of DCR clientele are local users. The degree to
which a particular DCR attracts users from outside the immediate
area is likely to reflect the nature of the local market. If the local
drug market is used regularly by people outside the area, this will
be reflected in the clientele of the DCR.
The degree of public nuisance experienced by local residents and
businesses will depend on the dynamics of the local situation and
is likely to vary over time. Research has also shown a key issue
here to be the degree of co-operation and planning between local
agencies. Variations in these local contexts have been associated
with (often temporary) increases in DCR-related public nuisance in
some areas but decreases in others.
While dealing has taken place in the vicinity of DCRs, this appears
to be controllable through strict DCR rules and street policing.
There is no evidence of either increases or decreases in crime
consequent on DCR implementation, although this is unsurprising
as DCRs do not provide prescription drugs and cannot therefore
directly affect crime committed to obtain drugs. However, to the
extent that DCRs are successful in providing access to structured
treatment and other interventions aimed at social integration, they
may have an indirect impact on crime levels.
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How do they compare to other interventions and
are they cost-effective?
Other interventions
The IWG is clear that DCRs need not only to be effective, but to be
more effective than other similar interventions. This raises the
question of which aspects of DCR provision are covered by other
interventions. To the extent that DCRs provide clean injecting
equipment, they serve a similar purpose to needle and syringe
exchange programmes (NSPs). NSPs can also provide advice on
safe injecting and thereby attempt to impact on users’ health and
overdose. In some cases, nursing staff also provide ancillary
medical services such as immunisation against hepatitis B and
wound care and may make onward referrals. Moreover, the client
groups are broadly similar, with sizeable proportions of homeless
and public drug users. However, the fact that in DCRs injections
take place on site means that it can be virtually assured that
injections take place comparatively safely (with sterile equipment
and in less dangerous places on the body etc.). Supervised
injecting also means that immediate intervention can be made in
overdose incidents and the direct observation of injecting
behaviour should result in more tailored, personalised advice on
injecting. DCRs should also have a much greater potential to
impact on public drug injecting and associated public nuisance by
bringing injecting episodes inside the facility.
Outreach workers can also work with users to reduce the risks
associated with their drug use, provide sterile injecting equipment
and refer users on to other agencies but, as with the comparison
with NSPs, by supervising injecting on site, DCRs are able to
reduce risks in other ways. However, it should be noted that
outreach workers would be able, potentially, to reach and work with
those users not prepared to come into DCRs to inject. There may
be, for example, a group of homeless users who do not want to
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use in a DCR because they have been excluded from injecting
there or simply because they do not want to. Outreach offers a
method of reaching such a group.
Emergency services obviously respond to overdose incidents.
However, there is always some delay, which can be critical,
between recognition of an overdose incident and the arrival of
trained staff. DCRs clearly offer the potential to respond more
quickly to the overdose events that occur within them and,
possibly, those taking place nearby.
From such considerations the IWG concludes that DCRs offer a
number of services that cannot be delivered, or cannot be
delivered as effectively, by other approaches.
Cost-effectiveness
Different operational models are likely to incur very different costs.
Stand-alone demonstration projects seem most likely to be the
most expensive models, whereas services integrated with other
components of drug treatment seem likely to be cheaper.
The Sydney MSIC operating cost for one year was the equivalent
of approximately £850,000 (MSIC Evaluation Committee, 2003, p.
214). The annual cost of the Canadian SIS trial was the equivalent
of approximately £1,200,000, although this also includes the
evaluation expenses (City of Vancouver Four Pillars Drug Strategy,
2003). However, these represent the very top end of the scale,
being large, stand-alone demonstration projects. Cost data on
European services, some of which operate on an integrated model,
are not readily available. Nevertheless, the marginal costs of
extending a service to include a supervised consumption facility
must inevitably be much less than those arising from a specialised
project such as the MSIC and SIS.
64
Report of the IWG on Drug Consumption Rooms
While it has been concluded from the research evidence that
DCRs have an impact on a range of outcome measures, the size
of this impact is much harder to ascertain. As a result, at this stage,
it is impossible to say anything certain about cost-effectiveness.
However, integrated DCRs that provide a service to large numbers
of injecting drug users seem most likely to offer the best ‘value for
money’, particularly in terms of overdoses avoided and the early
treatment of injection-related infections.
Bringing together evidence of need and evidence
of effectiveness
The IWG concludes that DCRs are effective in providing safe and
clean injecting environments, advice on safer injecting and on-site
medical and counselling interventions. Thereby, they have a
significant impact on preventing the escalation of overdose
incidents and there is convincing evidence that they prevent
overdose deaths. They also contribute to the better health of users,
provide opportunities to link with structured treatment and may well
prevent the spread of blood-borne viruses. They clearly can reduce
injecting in public places, discarded syringes and drug-related litter.
The IWG is mindful that all of these impacts depend crucially on
precisely how DCRs are implemented. For example, DCRs are not
likely to have an impact on public drug use if they are open for only
a few hours a day. Likewise, evidence from Germany clearly shows
that if a DCR is set up some distance from a local drug market, it is
unlikely to attract many users and have much of an impact.
However, assuming DCRs were well designed and well
implemented, would they have an impact on drug-related problems
in the UK, as identified in Chapter 3? The IWG’s response to this
question is that they would almost certainly have an impact on
some of these problems. The frequency of overdose, the
prevalence of blood-borne viruses and other injection-related
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infections, the amount of public injecting and the damage caused
to communities in the UK would all be addressed, at least to some
degree, by DCRs. While other already existent services also
address some of these needs, it is clear that DCRs offer the unique
potential to ensure safer, on-site injecting and thereby directly
prevent health problems, overdose and drug-related nuisance.
The IWG considers that DCRs have a particular potential to impact
on the serious health and social problems associated with two
overlapping groups in the UK: homeless drug users and those that
inject in public. The potential dividends in terms of reduced
damage to communities, improved health and saved lives seem
much greater for these groups. The possibility of designing DCRs
that focus particularly on these groups is considered in Chapter 6.
However, before turning to such issues, it is important to consider
the social and legal obstacles that lie in the way of setting up DCRs
in the UK.
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The IWG shares others’ discomfort at the idea of letting people
bring dangerous, controlled substances to a place where they are
then allowed to inject them into their bodies. Such a scenario
throws up a number of legal and ethical concerns: for example,
would DCRs be against the law in this country? Would they
contravene the United Nations Drug Conventions? Might they also
serve to condone the use of controlled drugs? The IWG has also
been aware that there are, undoubtedly, substantial political
obstacles lying in the path of any experimentation with DCRs in the
UK. It is a highly sensitive idea that is likely to cause alarm to
many. Politicians may feel that it would be impossible to have a
serious and open debate about this question, given previous media
and public opposition to the idea of ‘shooting galleries’. Such
concerns were put forward by the Home Office in its evidence to
the Home Affairs Select Committee (see Chapter 2). Finally, there
are the local concerns. Could any local community be expected to
host a new DCR with equanimity? While the international evidence
reviewed in the last chapter may refute such views, there will
inevitably be deep suspicions that a DCR will attract even more
dealers and users to a local area.
This chapter explores these barriers and concerns, with separate
sections below focusing on the legal, ethical, political and local
barriers to the establishment of DCRs.
Legal barriers
Two papers have been commissioned which have greatly informed
the IWG’s consideration of the legal issues (Fortson, 2006a;
2006b). Readers are referred to these papers for a fuller account of
the complexities in this area.
5 Potential barriers and
concerns
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There are two key aspects to legal questions concerning DCRs:
first, whether DCRs breach the three United Nations Drug
Conventions; and, second, whether operating a DCR would put
individuals at risk of prosecution under United Kingdom law.
The UN Conventions
There are three United Nations Conventions dating from 1961,
1971 and 1988 and the UK is a signatory to all three. These
Conventions provide the framework for international co-operation
in the drugs field. Their main focus is on drug production and
trafficking but sections are included which focus on possession.
The 1961 Convention (to which a protocol was added in 1972) was
introduced, in part, to unify and simplify the nine international
agreements that were already in place but also to extend existing
controls to drug cultivation (Jamieson, 2001). Its main aim was to
ensure that ‘narcotics’ could only be produced and supplied for
medical and scientific purposes. However, it also required states to
make the possession and purchase of narcotic drugs ‘punishable’
offences when committed intentionally (although there has been
doubt over whether these measures were intended to cover
possession for personal use: Independent Inquiry into the Misuse
of Drugs Act, 2000). The 1972 protocol to the 1961 Convention
strengthened controls over production and trafficking and
emphasised treatment and rehabilitation as alternatives (or
additions) to punishment (Jamieson, 2001; Fortson, 2006b). This
latter emphasis was also reflected in the general provision within
the 1961 Convention that ‘parties’ or signatories ‘shall give special
attention to and take all practicable measures for the prevention of
abuse of drugs and for the early identification, treatment,
education, after-care, rehabilitation and social reintegration of the
persons involved’ (Article 38, para. 1, p. 19). As Fortson (2006b)
points out, the Conventions are not just about control, they also
exhort signatories to rehabilitate and reintegrate drug users. The
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1961 Convention also paved the way for the establishment of the
International Narcotics Control Board (INCB), the watchdog
responsible for monitoring compliance with the Conventions, which
was then set up in 1968.
The 1971 Convention was a response to the increased use of
drugs not covered in the earlier Convention, such as various
stimulants, sedatives and hallucinogens, and imposed restrictions
on these drugs similar to those introduced in the 1961 Convention.
The 1988 Convention sought to clarify some of the ambiguities in
the earlier Conventions and to strengthen and supplement them
principally in the context of illicit trafficking of scheduled
substances. Most importantly in the present context, it specified
that the possession, purchase or cultivation of illicit drugs for
personal consumption should be criminal offences when committed
intentionally. However, again, measures such as treatment,
education, aftercare, rehabilitation and social integration may be
substituted for (or added to) conviction and punishment (Jamieson,
2001). The welfare and rehabilitation of users is also emphasised
elsewhere, with signatories being exhorted to ‘adopt appropriate
measures aimed at eliminating or reducing illicit demand for
narcotic drugs … with a view to reducing human suffering and
eliminating financial incentives for illicit traffic’ (Article 14, para. 4,
p. 14). Furthermore, the UN’s own legal advisers on the
Conventions have pointed out in an unpublished paper that the
1988 Convention authorises signatories to base demand reduction
measures on the recommendations of the United Nations. The
resolution relating to demand reduction1 is therefore relevant
(UNDCP Legal Affairs Section, 2002). This resolution pledged ‘a
sustained political, social, health and educational commitment to
investing in demand reduction programmes that will contribute
towards reducing public health problems, improving individual
health and well-being, promoting social and economic integration’
(UNDCP Legal Affairs Section, 2002, p. 8).
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There are therefore two themes running through the UN
Conventions: on the one hand, there is a strong emphasis on
controlling the production, distribution and possession of drugs,
which has been the focus of most commentators. On the other,
there is a clear and repeated emphasis on the rehabilitation and
integration of drug users and, indeed, on the general health and
welfare of all people (Fortson, 2006b). Given this second aim,
there is latitude within the Conventions for the introduction of harm
reduction measures that aim to improve the health of users and
contribute to their welfare, rehabilitation and reintegration (Fortson,
2006a).
Turning specifically to the question of DCRs, in 2002 the Legal
Affairs Section of the United Nations Drug Control Programme
(now the United Nations Office on Drugs and Crime) produced an
opinion for the INCB on the flexibility of the Conventions with
regard to harm reduction approaches (UNDCP Legal Affairs
Section, 2002). The question of whether or not DCRs contravene
the Conventions was specifically considered in this paper:
It might be claimed that this approach [DCRs] is incompatible
with the obligation to prevent the abuse of drugs … It should
not be forgotten, however, that the same provisions create an
obligation to treat, rehabilitate and reintegrate drug addicts,
whose implementation depends largely on the interpretation
by the Parties of the terms in question. If, for example, the
purpose of treatment is not only to cure a pathology, but also
to reduce the suffering associated with it (like in severe-pain
management), then reducing IV drug abusers exposure to
pathogen agents [such as HIV and hepatitis] should perhaps
be considered as treatment.
(UNDCP Legal Affairs Section, 2002, p. 5)
The paper goes on to consider whether DCRs might be said to
incite or induce the illicit use of drugs or aid, abet or facilitate the
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possession of drugs, contrary to the Conventions. It points out that
these matters could only count as criminal offences ‘when
committed intentionally’ and contends that it is hard to assert that
DCRs intentionally incite or induce illicit drug use or that they
facilitate possession:
On the contrary, it seems clear that in such cases the intention
of governments is to provide healthier conditions for IV drug
abusers, thereby reducing their risk of infection with grave
transmittable diseases and, at least in some cases, reaching
out to them with counselling and other therapeutic options.
(UNDCP Legal Affairs Section, 2002, paras. 27 and 28)
Thus the UN’s own legal experts on the Conventions have
concluded that DCRs do not necessarily contravene them. But this
is manifestly not the view of the organisation for which this legal
opinion was prepared: the INCB. As stated in Chapter 2, each year
in its report summarising the world situation with regard to treaty
compliance, the INCB expresses its belief that DCRs are contrary
to the Conventions. The grounds for this view have varied a little
over the years: in the 1999 report the primary view expressed was
that DCRs facilitate drug trafficking (INCB, 2000, p. 26). In the
2000 report the main reference was to DCRs breaching the
principle that drugs should be used solely for medical and scientific
purposes (INCB, 2001, p. 66). In the 2002 report there was
concern about ‘aiding and abetting drug abuse (and possibly illicit
drug trafficking)’ (INCB, 2003, p. 70). By the 2003 report, there was
a more measured appraisal, including the observation that the
German DCRs were ‘perceived as a success by a large part of the
local authorities and the local population’ (INCB, 2004, p. 78).
However, the report went on to assert that there was little evidence
that DCRs ensured that users underwent treatment or reduced
drug-related deaths. Moreover, in that they allowed the abuse of
illicit drugs, they were contrary to the Conventions (INCB, 2004,
p. 78). The 2004 report (INCB, 2005) recognised that the
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establishment of DCRs is a contentious issue and that some argue
that they have positive effects. However, the INCB ‘reiterates that
drug injection rooms are against the central principle embodied in
the international drug control treaties, namely that the use of drugs
should be limited to medical and scientific purposes only’ (INCB,
2005, p. 77). Finally, the 2005 report reiterates the INCB position
that DCRs contravene ‘the major principle of the treaties, namely
that the use of drugs should be limited to medical and scientific
purposes’ and ‘deeply regrets’ the opening of the DCR in Norway
(INCB, 2006, p. 84).
There is therefore considerable disagreement between the UN’s
legal experts and the INCB on these issues. What is clear from any
reading of the 1988 Convention is that the unauthorised
possession of controlled drugs for personal consumption should be
a criminal offence under a signatory’s domestic law when
committed intentionally. However, beyond this, as Jamieson (2001)
has pointed out, there appears to be ‘considerable room for
manoeuvre’.
Turning from the question of possession to the potential role of the
DCR in ‘publicly inciting or inducing others … to use narcotic drugs
or psychotropic substances illicitly’ and ‘facilitating’ the commission
of a drug offence (Article 3, paragraphs (c) iii and iv), the Legal
Affairs Section’s arguments seem convincing with regard to inciting
or inducing: it is hard to see how a DCR could be shown to do
these things intentionally. While DCRs expressly aim to facilitate
safe injecting, it is not their purpose to facilitate unlawful,
unauthorised possession for personal consumption.
Perhaps a stronger argument of the INCB is that DCRs are
contrary to the Conventions because they appear to run against
the ‘central principle’ that ‘the use of drugs should be limited to
medical and scientific purposes only’. This phraseology appeared
in the 1961 and 1971 Conventions but not the 1988 Convention.
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The relevant paragraph of the 1961 document reads:
A Party shall, if in its opinion the prevailing conditions in its
country render it the most appropriate means of protecting the
public health and welfare, prohibit the … possession or use of
any such [Schedule IV2] drug except for amounts which may
be necessary for medical and scientific research only,
including clinical trials …
(Article 2, para. 5(b))
The Official Commentary on the 1961 Convention makes it clear
that this paragraph was introduced as a compromise, leaving the
question of prohibition to the judgement of each party (see Fortson,
2006b). Furthermore, whether or not ‘possession’ as defined in the
1961 and 1971 documents referred to personal use as opposed to
possession in the context of trafficking offences has been much
contested (Jamieson, 2001). The 1988 document sought to clarify
these issues and it did so without explicit reference to scientific or
medical use (although it did reaffirm ‘the guiding principles of
existing treaties … and the system of control which they embody’
(p. 1)).
Literal interpretations of the Conventions are difficult: there is,
inevitably, a considerable degree of ambiguity conferred by the
three historical layers of the Conventions and the many paragraphs
relating to the same issues. The INCB’s plea that DCRs are
contrary to the Conventions might best be understood as implying
that they are at odds with the spirit of the Conventions: in their own
words, that the restriction of the use of controlled drugs is the
‘central principle’ (INCB, 2005). However, it could also be argued
that the central aim of the Conventions is to bring about
international co-operation on drug trafficking. Beyond this, there
are many subsidiary aims and emphases, some of which seem to
conflict.
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As Fortson points out, ‘Conventions, in common with many formal
documents, need to be given a purposive interpretation’ (Fortson,
2006b, p. 4). It is equally clear that different commentators will give
different interpretations. The Conventions do not seem to represent
an insuperable obstacle to the implementation of DCRs: the fact
that DCRs have been set up in seven countries which have signed
the three Conventions and one (Switzerland) that has signed the
first two attests to this. An important question is therefore how
other countries have rationalised the introduction of DCRs with
their status as signatories to the UN Conventions.
Switzerland
In Switzerland, the Swiss Federal Office for Public Health
commissioned two key legal analyses (Hedrich, 2004). The first of
these, published in 1989 following the setting up of the first DCR,
focused on the status of DCRs within national legislation. The
second, which was not produced until 2000, focused on
international law and the drug Conventions in particular. By this
point, DCRs had been operating in Swizerland for 12 years. This
paper3 states that:
No guidance at all is provided [in the Conventions] to the
persons who must decide whether or not state-controlled
public injection rooms are conducive to the rehabilitation and
social reintegration of addicts, to the reduction of human
suffering and to the elimination of financial incentives for illicit
traffic. This is indeed not a legal question at all, in the sense
that medical experts, social workers and health policy makers
are much better equipped than lawyers to provide reliable
responses.
The Swiss position therefore appears to be that because the
Conventions do not provide explicit guidance on the question of
DCRs, governments need to decide for themselves whether DCRs
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would contribute to UN goals, such as reducing human suffering
and trafficking.
Germany
In 1993 an analysis of the same question was undertaken by the
Chief Public Prosecutor in Frankfurt (Körner, 1993, referenced in
Hedrich, 2004). The conclusion was that DCRs did not constitute a
punishable offence according to German law or the Conventions,
provided that the sale, acquisition or passing on of drugs is not
tolerated and that hygienic, stress-free and risk-reduced drug
consumption is ensured through adequate care and control.
Since this time, federal legislation has been introduced which
explicitly enables cities to apply to set up DCRs.
Canada
The main law governing drugs in Canada, the Controlled Drugs
and Substances Act 1996, allows for exemptions from the Act if, in
the opinion of a minister, ‘the exemption is necessary for a medical
or scientific purpose or is otherwise in the public interest’ (Fortson,
2006b, p. 2). In 2003, the Canadian health minister granted such
an exemption for the establishment of a pilot research project, and
therefore necessary for a ‘scientific purpose’. As Fortson (2006b)
points out, the Canadian Government therefore believes that it has
complied with the Conventions: the operation of evaluated pilot
DCRs effectively restricting use to scientific purposes.
Australia
In Australia, the Drugs Misuse and Trafficking Act 1985 was
temporarily amended to enable the MSIC project to be piloted.
Under this legislation, a DCR has to be licensed and the granting
of that license is subject to a number of restrictions and conditions
(such as proximity of the premises to a school). Sections 36O and
36P provide exemption from criminal and civil liability for acts
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carried out in good faith and without recklessness or gross
negligence. Section 36N enables users to be in possession of
drugs in the licensed DCR.
Conclusion
The IWG concludes that well-run DCRs would not act contrary to
the primary objects of the three United Nations Conventions. The
extent to which DCRs might contribute towards meeting some of
the Conventions’ objectives concerning user welfare, rehabilitation
and reintegration would depend on the extent to which other
services were provided and referrals made. An ‘integrated’ model
of DCR provision, which includes a range of health, treatment and
social integration services, would seem to be most Convention
compliant.
Signatory states have employed various techniques and
arguments to rationalise the introduction of DCRs with their status
as signatories to the Conventions. The danger here is that the
operation and implementation of DCRs can be compromised by
shoehorning them into the perceived (but we think misconceived)
Convention-compliant construction of the relevant provisions. In
any event, the IWG finds it unacceptable that a restrictive
construction of the Conventions that places undue emphasis on
scientific and medical use should result in countries setting up
DCRs as perpetual experiments. In this context, the IWG
emphasises that the Conventions were drawn up at a time when
there was little or no awareness of harm reduction interventions
such as DCRs. As a result, there is no clear guidance on the
question of DCRs (De Ruyver et al., 2002). There seems little point
in repeatedly analysing these texts for indications and suggestions
that might apply to DCRs: indeed, there is a sufficient lack of clarity
to allow any commentator to reach the conclusion that they wished
to reach at the outset. Given this, the IWG concludes that the
Conventions should be interpreted as offering general guidance
rather than specific precepts in this area, of which the need to
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prevent trafficking and contribute towards the rehabilitation and
social reintegration of users seems most pertinent.
Other international agreements
Fortson (2006b) has considered the argument that various
international agreements, and in particular the European
Convention on Human Rights (ECHR) enacted in the UK through
the Human Rights Act 1998, might actually make the Government
duty-bound to set up DCRs. However, the IWG accepts his view
that this is unlikely to be an argument that would find favour in a
United Kingdom court. Nevertheless, the emphasis in documents
such as the ECHR and the UN’s Declaration of Human Rights on
the dignity of ‘the human family’ and the right to life do have a
strong resonance in the context of DCRs.
Domestic legal obstacles
Fortson (2006b) explains how those who run and those who use in
DCRs could be liable to a number of criminal and civil actions. A
significant number of these stem from the Misuse of Drugs Act
1971 (henceforth the MDA).
The MDA
The following sections have relevance for DCRs (Fortson, 2006b):
 Production and preparation: Section 8 of the MDA prohibits
managers and occupiers of premises from ‘permitting or
suffering’ the production of controlled drugs in contravention of
section 4(1) of the MDA. The preparation of a drug may or may
not constitute ‘production’ under the MDA.
 Unlawful possession and consumption: Users are clearly in
possession of whatever drugs they bring to a DCR and have
therefore committed an offence. It is also likely that at various
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points a member of staff in a DCR would come into possession
of a controlled drug: for example, by finding a controlled drug
that has been left behind (as happened in the Sydney MSIC:
van Beek, 2004). With regard to project managers, following the
Government’s decision to repeal an amending provision to
section 8(d) of the MDA, it only remains an offence for an
occupier or manager of premises to ‘knowingly permit or suffer’
the smoking of cannabis or ‘prepared opium’ on the premises.
Thus staff could not be charged under section 8 for permitting
the use of heroin or cocaine on the premises.
 Supply: Any user who shares drugs with another user will have
committed an offence of supply under section 4. If user A asks
user B to inject him/her with heroin, then B is guilty of supplying
the drug (subject to the case of Harris [1968] 1 W.L.R. 769).
Such an act is also an offence under section 23 of the Offences
Against the Person Act 1861, because heroin has been held to
be a ‘noxious thing’. Managers and ‘occupiers’ of DCRs would
be committing an offence under section 8 if they were to
‘knowingly permit or suffer’ the supply or attempted supply of a
controlled drug in contravention of section 4.
 Paraphernalia: Workers in DCRs would be restricted in the type
of paraphernalia that they could legally provide to users. If they
were to provide sterile cookers, razor blades, plastic film,
aluminium foil or tourniquets they could be in breach of section
9A. It is unclear how many prosecutions have been brought
under this section but the possibility of prosecution would
remain.
The Offences Against the Person Act
Anyone injecting someone else with heroin (whether or not they
have requested them to do so) is guilty of administering ‘a noxious
thing’, contrary to section 23 of the Offences Against the Person
Act 1861. There is doubt about the degree to which someone less
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directly helping a user to inject might also be liable and this is an
area that would benefit from clarification (Omerod and Fortson,
2005).
Manslaughter
If a person directly injects another with heroin unlawfully in a DCR
and death of the latter results, the injector may be guilty of
manslaughter. Moreover, a person may also be liable for
manslaughter if they assisted another in the injection process. This
is a complex area of law and one which is likely to be considered
by the House of Lords in 2006 (Ormerod and Fortson, 2005).
There is the potential for DCR employees to be charged with
manslaughter if they act in circumstances that constitute assisting
another in an unlawful injection process and death from heroin
intoxication results. Prosecution in such a case may well not be
brought on public interest grounds but a civil action might be
mounted if there were evidence of negligence.
Negligence and civil action
Those running DCRs would be subject to the legal obligations,
duties and requirements that affect other service providers. They
would need to meet health and safety requirements and attempt to
protect their employees from injury (particularly pertinent, given the
potential for needlestick injuries). They might also be liable to civil
action where things went wrong, e.g. when a user died or where a
member of staff was injured in negligent circumstances.
Anti-social Behaviour Act 2003
If there were reasonable grounds to suspect that conduct in a DCR
was causing serious nuisance or disorder, they could be closed
down under the Closure Order procedure in the Anti-social
Behaviour Act 2003. Closure proceedings are brought by the
police, rather than civilians.
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Implications and conclusions
There are therefore a number of potential legal obstacles to the
establishment of a DCR in the UK. Some of these could be
addressed through properly enforced rules, similar to those
instituted in DCRs abroad. Such rules would need to prevent the
sharing (and thereby ‘supply’) of drugs among users and users
injecting each other. They would also need to carefully define and
limit the level and nature of help offered to injectors by staff
(including the provision of paraphernalia). Rules would need to
carefully govern the safe disposal of needles, to prevent injury to
staff or users, and the action that should be taken if suspected
drugs are left behind by users. Clear procedures would need to be
set out for responding to overdose incidents. Lastly, nuisance and
disorder would need to be carefully controlled.
Ideally, were pilot DCRs to be set up, this would be with the
approval and support of the Government. This would mean that a
standard set of rules and minimum standards could be instituted
and enforced. It would also mean that, at some stage, DCRs could
be given statutory protection though primary legislation or by way
of a combination of primary and secondary legislation. Were there
not the political will in the UK to introduce primary legislation, it
would be possible to modify the reach of the Misuse of Drugs Act
1971 by secondary legislation in order to provide a significant
degree of protection from prosecution under this Act.
However, while such legislative change would provide a very safe
basis for piloting DCRs in the UK, the IWG is not persuaded that
this would be a necessary and unavoidable first step. Pilot DCRs
could be set up with clear and stringent rules and procedures that
were shared with – and agreed by – the local police (and crime and
disorder partnerships), the Crown Prosecution Service (CPS), the
Strategic Health Authority and the local authority. An ‘accord’ might
be established that action would not be taken against the DCR, its
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staff and, in normal circumstances, its users. The local police and
CPS would need to agree that they would not charge users for
possession offences within the DCR or on their way to the DCR. Of
course, they would arrest users suspected of other offences in the
usual way. Such local agreements have allowed DCRs to be set up
in Frankfurt.
There are potential problems and risks associated with such an
approach. The accord would be agreed between the particular
individuals managing the local agencies at that time. A change of
senior staff could lead to its collapse. There is also nothing to
prevent local citizens or businesses from initiating a private
prosecution. However, provided DCRs institute the type of rules
referred to above and are properly insured, the IWG is of the view
that risks and problems can be kept within acceptable limits.
Were the Government to withhold its support from the piloting of
DCRs, the IWG does not think that this should preclude the
development of such projects locally. Again, local agencies would
need to work together and draw up an accord which defined their
different roles. The potential for police forces to trial approaches at
a local level that are not sanctioned by government is exemplified
by the Lambeth cannabis policing pilot, where a senior police
officer introduced a system of formal street warnings for cannabis
possession offences in South London. The IWG sees no
compelling reason why such an approach could not be taken with a
DCR, although it would require the sustained commitment of a
number of senior individuals across the key agencies. IWG
members visited a number of projects on the continent where this
type of ongoing, close liaison between the key agencies had been
achieved through regular interagency meetings.
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Ethical concerns
A likely concern for many is that the setting up of DCRs would
condone the use of drugs in a more general sense. An important
function of the law and of official policy is their symbolic value: they
make a statement about what is acceptable and what is not
acceptable in society. Should the state officially sanction DCRs, the
Government’s broader, and currently strong, opposition to Class A
drugs could be eroded and this might have a knock-on effect on
people’s propensity to use Class A drugs. It might also be claimed
that such a policy change would signal a general ‘soft on drugs’
approach which might encourage young people to experiment with
drugs. This concern is echoed in the debate about the
classification of cannabis: where there have been fears that the
reclassification of cannabis from Class B to Class C ‘sent the
wrong message’ to young people.
At this point, it is impossible to either verify or disprove such views:
DCRs have not been introduced in the UK and evaluations in other
countries have not attempted to address the question of the impact
of such developments on broader drug-related attitudes and use.
The IWG considers it unlikely that such an approach with
dependent, injecting drug users will have a significant impact on
the drug use of young people, who tend to have very negative
attitudes towards such users (Fountain et al., 1999). However, the
best way to address this issue would be to include questions about
the broader impact on attitudes and use in an evaluation of pilot
projects. Community surveying could include samples of young
people, to see whether there appeared to be any impact of a DCR
in their locality.
Other concerns may revolve around DCRs acting as a ‘Trojan
Horse’, allowing a legalising agenda to be smuggled into the drug
policy fortress. This has certainly not been an aim of the IWG and it
seems perfectly possible, as the last two decades have shown, for
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the Government to develop harm reduction approaches within a
broadly prohibitionist approach to controlled drugs.
More specific dilemmas are associated with the potential for DCRs
to encourage drug injecting as opposed to other modes of use or
encourage users to take greater risks. Our consultation with drug
users provided the IWG with a difficult possible scenario: if one
member of a couple usually injects and the other usually inhales,
and if they usually purchase and use their drugs together, might
the drug inhaler be tempted into injecting by visiting an injection-
only DCR with his/her partner? There is at least a theoretical
possibility that this could occur but it is unclear how common it
would be for such a situation to arise. Other users involved in the
consultation felt that this would be very rare indeed. Again, this
issue would best be addressed through pre-piloting questionnaires,
which would be able to assess the likelihood of such situations
arising, and then careful evaluation of the operation of pilot
projects.4
It would also, similarly, be hard to identify whether DCRs were
encouraging non-injectors to inject for the first time. This issue has
been addressed in some of the evaluation evidence and it appears
rare for such circumstances to arise (Hedrich, 2004). A number of
considerations are relevant here. On the one hand, it is plausible
that users may wish to hide the fact that they were injecting a drug
for the first time, making the research evidence somewhat
questionable. However, on the other, there is evidence to suggest
that injecting initiates are most often introduced into injecting by
another user (Stenbacka, 1989; Crofts et al., 1996; Hunt et al.,
1998). This would not be allowed in the large majority of DCRs
and, given the technical difficulty of the task, it seems unlikely that
a user would attempt their first injection without any assistance
from others.
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DCRs might also provide a false sense of security, encouraging
users to try more risky amounts of a drug, more risky preparations
(such as crushed tablets) or more risky drug combinations. Again,
this would need to be a subject for evaluation, so far as such
trends in use could be ascertained. However, the IWG considers
the fact that only one person has been reported to have died in a
DCR to point to either the low prevalence of such drug use
behaviours or the success of DCRs in preventing deaths occurring
when these behaviours did take place.
Finally, whatever the rarity of deaths in DCRs, there is still the
possibility that a death will occur. If a user were to die in a UK
DCR, could it sensibly be claimed that this policy had effectively
allowed, or even aided, someone to take their own life? The legal
position in this regard has been referred to above but people might
well see this as an ethical issue. The IWG views the main
consideration here to be that, provided proper procedures were in
place and followed, it is highly likely that this user would have died
wherever they were injecting. It is clear that, overall, DCRs make a
considerable contribution to the survival of users.
Political concerns
When the Government last considered a recommendation to pilot
DCRs, from the Home Affairs Select Committee, it voiced a
number of concerns which were listed earlier in the report. Now
that the evidence has been reviewed in the subsequent chapters,
these issues are revisited:
 National and international legal issues: DCRs would
‘contravene or undermine UN conventions or the Misuse of
Drugs Act’.
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As has been concluded above, the United Nations Drug
Conventions do not provide clear guidance on whether DCRs are
incompatible with UK treaty obligations. DCRs certainly contribute
to some of the aims of the Conventions and may fall foul of others,
depending on interpretation. The fact that eight signatories to the
Conventions5 have introduced DCRs, on a number of different
grounds, testifies to the range of interpretations that are possible.
With regard to the Misuse of Drugs Act, as stated above, the IWG
concludes that many of the potential contraventions could be
sensibly addressed through a set of clear and well-enforced rules.
However, the offence of possessing a Class A drug would
inevitably occur within a DCR. The IWG believes that this issue
could be dealt with through an accord agreed between the key
local agencies, including the local police and branch of the CPS.
This accord would ensure that, in normal circumstances, the local
police would not charge users for possession offences within the
DCR or on their way to the DCR.
 ‘The Government could be accused by the media and others of
opening “drug dens”.’
The IWG accepts that some local and national media are likely to
be critical of the idea and would attack the Government were it to
support the introduction of DCRs. However, all drug policies are,
quite rightly, contested by different groups and different
commentators. The IWG considers the standard of media debate
on drug policy issues to have improved over the past five years:
while many will fundamentally disagree with the idea of DCRs, it is
to be hoped that commentators will employ argument rather than
invective. The IWG is keen to see a serious and well-contested
public debate on the DCR question.
 ‘No guarantee that public or political tolerance will be the same
as Switzerland.’
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The IWG accepts that one could not expect the same sort of
response to the idea in the UK as that experienced in Switzerland.
However, the IWG does not see any reason to expect that
reactions in the UK would necessarily be more hostile than those
experienced in Germany, Norway or Australia, countries that have
introduced DCRs but which are not particularly associated with
tolerant attitudes towards controlled drugs.
 ‘Will directly increase health service costs as they would be a
new service provision requiring additional capital and revenue
costs.’
The cost of DCRs will depend on where and how they are
implemented. If, as is discussed in the next chapter, they are
introduced as adjuncts to current drug services, the marginal costs
will be quite low. Moreover, one of the key arguments for piloting
DCRs is the opportunity this would provide for a rigorous analysis
of cost-effectiveness.
 ‘Still leave the possibility of unsafe injecting during the hours
they are closed.’
The degree to which DCRs are able to ‘capture’ unsafe injecting in
a local area is a key measure of their success. Opening hours and
location are important features likely to govern accessibility and
use. The need to work with other agencies and services is also
important in this context. IWG members found from their visits to
DCRs abroad that, where there were more than one DCR in a city,
projects were able to stagger their opening times and persuade
users to move on to another DCR or a hostel at closing time.
 ‘There may be problems in some areas on occasion with drug
dealers congregating near to venues, leading to reduced local
tolerance for the presence of injecting rooms in their
neighbourhood.’
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 ‘Likely to raise the issue of policing low-level dealing in the
vicinity of injecting rooms.’
These are, undoubtedly, potential problems but ones that have
been successfully dealt with elsewhere through close partnership
with the local police, who are encouraged to crack down on anyone
suspected of dealing within a certain radius of a DCR.
Differentiating between dealers and users is not a straightforward
process, as recent research has shown (May et al., 2005). Many
dealers also use drugs and users often buy drugs together and
share their drugs (which technically involves the ‘supply’ of drugs).
However, in projects abroad, users in general are discouraged
from ‘hanging around’ in the immediate neighbourhood and this is
usually enforced by the local police.
 Could lead to damaging confusion between DCRs and heroin
prescription.
As outlined in the Introduction, DCRs are clearly differentiated from
heroin prescription in terms of both their operation and their target
group. The IWG is fully supportive of the heroin prescription trial
but emphasises that the chaotic, excluded users targeted by DCRs
represent a very different group from the relatively stable,
entrenched, long-term users enrolled on heroin prescription
programmes.6
 ‘… we have no evaluations of those developed in other
European countries.’ There is a lack of evidence on ‘the impact
of such facilities on local communities’.
As we have seen, there are now a considerable number of
evaluations from Europe, Australia and Canada. Many of these
studies do address the question of impact on local communities
and this has been given close attention by the IWG. As Hedrich
(2004) concludes, the evidence shows that ‘when managed in
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consultation with local authorities and police, they do not increase
public order problems by increasing local drug scenes or attracting
drug users and dealers from other areas’ (Hedrich, 2004, p. 83).
However, where interagency working is poor, problems can occur.
The most robust evaluation of the impact of a DCR on local
residents and businesses at an aggregate level showed increasing
support for the DCR and decreasing concern about attracting drug
users from outside the area, when community views were
compared before and after the DCR’s implementation (Thein et al.,
2005). Moreover, if introduced as extensions to already existing,
needle-exchange facilities (see next chapter), the impact on local
communities may be kept to a minimum.
None of these concerns therefore seem to be insurmountable. A
political decision to support the introduction of DCRs would
undoubtedly attract opprobrium from some but, if the Government
accepts the potential for DCRs to decrease the damage caused to
individuals and communities by injecting drug use, politicians may
have to grasp the nettle.
Local concerns
If DCRs were to be piloted in the UK, there may well be
considerable local opposition to the idea. By providing something
that users want, the fear is that a DCR would act as a magnet,
drawing in users from other parts of the city or other areas of the
country. This issue has been discussed at some length in the last
chapter. As was concluded there, experience abroad has shown
DCRs to be used largely by local users. The degree to which users
from outside an area visit a particular DCR is likely to relate to the
nature of the local drug market: if users from a wide area
‘commute’ in to buy their drugs, this will be reflected in a DCR’s
clientele. However, users are unlikely to travel any distance
specifically to use a DCR, their primary motivation being to buy and
use their drugs as quickly as possible.
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It should be emphasised that many of the communities which might
be targeted for a DCR already suffer significantly from drug-related
nuisance, as the research undertaken by Taylor et al. (2006)
showed. The IWG considers that a well-designed and implemented
DCR offers the potential to lessen the overall impact of drug use on
a community and whether or not this is the case would be one of
the primary questions for an evaluated pilot. Great care would have
to be taken in positioning a pilot DCR, involving careful mapping of
the flows of drug users through a particular area. It seems to the
IWG that the most acceptable place for a DCR is a harm reduction
facility, such as a needle exchange, that already provides services
for injecting drug users, thus limiting the additional impact on the
local community.
Conclusion
The IWG is clear that the UN Conventions are not a significant
block to the implementation of DCRs in the UK. DCRs would
contribute towards many of the aims contained within the
Conventions. Moreover, the relevance of the Conventions to
modern harm reduction measures is highly questionable. United
Kingdom law also does not appear to present an insurmountable
obstacle. Provided a clear set of properly enforced rules are
instituted and local accords are forged between the key agencies,
the IWG concludes that DCRs could be piloted within the UK
without legislative change. Risks would remain but the IWG has
concluded that the potential benefits substantially outweigh these
risks. At some stage in the future, should DCRs prove their worth, it
would be important to introduce primary and/or secondary
legislation in order to fully protect those involved in the
management of the premises and those using drugs within them.
Many of the ethical concerns surrounding DCRs are best tested
through a rigorous evaluation of trial projects. Others may simply
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need to be discussed as part of the wider public debate on the
worth of this idea, which the IWG hopes will follow publication of its
report.
Political fears are perhaps the most important obstacle to the
piloting of DCRs in the UK. The IWG is clear that the evaluation
evidence warrants experimentation with this approach but it also
recognises that policy has never been solely evidence-based.
Supporting DCR pilots would undeniably represent a political risk
but one that should ultimately yield benefits for users and
communities. While the concerns voiced by the Home Office to the
Home Affairs Select Committee represented significant issues, the
IWG does not regard any of them as intractable problems.
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This chapter looks at the operation of DCRs in more detail and
draws some conclusions on what pilot DCRs might look like in the
UK. It is divided into three sections. The first identifies three DCR
models and a number of key domains in which they differ. The
second considers which approaches might apply best to the British
situation and how they might be implemented as pilot projects in
this country. The final section focuses on the need for evaluation.
DCR models
Hunt (2006c) provides a good overview of the history, objectives
and procedures associated with DCRs in seven of the eight
countries which host them.1 The purpose of this section is to
explore in more detail how DCRs differ in terms of their aims,
design and operation. In order to do this, three variants in DCR
design and delivery are described which draw on both the IWG
members’ visits to various DCRs and the published literature.
These are anonymised, composite projects which are not based on
any one DCR and are offered as examples which bring out the
main variations between projects.
6 UK pilots
Model 1
This DCR was set up in response to both health and public order concerns
surrounding injecting drug use. It has one large injecting room and no
smoking room. Around 300 people inject drugs at the project each day. On
entering, there is a large room, with a number of chairs and a desk at
which users register. Users are asked what drugs they plan to use and are
asked to show their drugs to the workers at the registration desk. If there is
a place free in the injecting room, a standard set of drug-injecting
paraphernalia is handed to them from the registration desk. If the injecting
room is full, users have to wait before picking up their paraphernalia and
entering the room.
On going into the injecting room, users are shown to one of ten cubicles or
booths, running along the length of one wall. Each contains a stainless
steel surface fixed to the wall, a chair and a mirror covering the wall above
the level of the stainless steel surface. These booths resemble a line of
Continued
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toilet cubicles that have no doors. The users are therefore visible from
behind as they use their drugs and a project worker is stationed in a
position which gives the best view of the users in these cubicles.
On leaving the injecting booth, users go into a room with comfortable
chairs, where they are encouraged to spend a short while before leaving
the project. However, this room does not have the ambience of the ‘living
room’ described in model 2. Users are not encouraged to stay for very long
periods unless they appear to be heavily intoxicated. While some users are
well known to project staff, others are infrequent visitors and there is not,
therefore, the same type of contact between staff and users.
Because of the focus on injecting, and the sheer number of users,
emergencies are common: on average, once in every 300–500 injections,
making it an almost daily event. Members of staff are all trained to deal
with such emergencies. Equipment for assisting breathing, including
oxygen, is close at hand. Naloxone can also be administered by trained
staff, although this is rarely needed.
Rules are kept to a bare minimum. Users are asked not to share out their
drugs on the premises but doing so does not necessarily result in
exclusion. Users are allowed to inject in their neck or groin but staff work
with users to prevent this. Those receiving a prescription for methadone
are allowed to use the project; under 18s and heavily intoxicated users are
not. Any violence is taken very seriously and the majority of exclusions are
for fighting. However, every effort is made to try to include users wherever
possible, recognising that the most difficult people are often those most at
risk of overdose.
There is good interagency working around drug-related issues in this city.
The relationship with local businesses (there are no local residents) is
managed through regular local meetings.
Continued overleaf
Model 2
This DCR has been set up primarily to reduce the local public nuisance
associated with homeless dependent drug users. It works with a group of
35 local, highly marginalised, homeless drug users. Only members of this
group are allowed to use the facilities, which include a smoking room,
where heroin and cocaine are smoked, but no injecting room. Injecting
drug use is comparatively rare in this city.
The project is based around a central, ‘living room’ area, where there is a
café serving hot drinks and food and an extensive seating area with a
television. The room is warm and clearly designed to provide an attractive
place for homeless users to spend time off the streets.
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When users wish to use their drugs, they go down a staircase to another
part of the project where the drug consumption room is located. On entry,
they come to a small office, where project staff ask to see their drugs and
provide them with any sterile paraphernalia that they may need. Provided
there is space, users are then allowed to enter the consumption room,
which has large, internal windows in it, allowing a clear view from the small
office. The consumption room is quite small (approximately five metres
square) and there are two wooden tables and numerous chairs in the
room. There are posters on the wall and an informal ambience. There are
two plastic containers positioned at each end of the room for discarded
paraphernalia and litter.
The consumption room tends to be busy, with between five and ten people
smoking crack cocaine in pipes or ‘chasing’ heroin on strips of tinfoil.
Sometimes at the weekend, as many as 25 people share this room and
there is standing room only. Users are free to go to and fro between the
living room area and the consumption room.
Project workers are on good terms with the users, seeming to know most
of them well. This reflects the limited number of people using the project.
Users have to have a pass before they are allowed to use the project. Only
users known by project staff, the police and other agencies to be homeless
and causing nuisance on the streets are given a pass.
Arguing and fighting are an occasional problem but very rarely have the
police needed to be called. Overdose incidents do not occur thanks to the
exclusive focus on smoking.
Relationships with other agencies are good and regular consultations are
held with representatives from the local community.
Model 3
This project has also been set up in response to both public order and
health problems. While many of the most marginalised local users are
injectors, there is also a growing population of crack users – many of them
sex workers. This project therefore provides both an injecting and a
smoking room.
The consumption rooms were added to an already existent drug project on
this site. This project therefore has a number of facilities other than the
DCRs. These include a methadone treatment programme, a ‘living room’/
café and ten beds providing overnight hostel-style accommodation. The
consumption rooms are on the ground floor and have a separate entrance
door from the rest of the project (although the facilities are all conjoined by
a staircase). The injecting room does not have booths like those described
Continued
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in model 1 but has a stainless steel ledge at waist height that runs around
the room, creating a table at which users sit to prepare and inject their
drugs. It is busy, with a daily average of 200 people using it, and a member
of staff works in the room itself, providing advice and keeping a close eye
on the users. The smoking room is less busy, but still used by around 50
users a day. It is viewed through a CCTV camera, the screen being
watched at the entrance desk. The smoking room is similar to that
described in model 2.
A number of rules are clearly displayed. Users must not share drugs on the
premises or inject in the neck or groin. Violence or shouting is also against
the rules. Failure to comply with rules frequently leads to temporary
exclusion.
Once they have used in the consumption rooms, users are able to use the
‘living room’ area on the next floor. This provides coffee and snacks, and
lunch is cooked each day with the involvement of users who are paid by
the hour. As with model 2, users can go to and fro between the
consumption rooms and the living area. The project is open for long hours
and if users have nowhere else to go in the evening they can ask to sleep
in the accommodation section. The methadone programme clients are kept
strictly separate from the rest of the project.
As with model 1, the project is open to anyone but new arrivals must go
through a registration procedure and all users are given a unique code.
The smoking room has been successful in attracting local sex workers,
many of whom use crack.
Key dimensions
These models illustrate some of the variety in the approaches that
have been developed around the world. This reflects variations in
the actual and perceived needs at national, city and more local
levels. A number of key dimensions can be identified which
underlie these differences. The location of a DCR on each of these
dimensions carries important implications for how a project is
designed and run.
Injecting vs smoking
While model 1 focuses only on injecting, model 2 focuses only on
smoking and model 3 provides separate rooms for smokers and
injectors. If a project focuses mainly (or solely) on smoking, there
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will be considerably less risk of overdose incidents.2 The degree of
supervision and the standards of hygiene in a smoking room can
therefore be lower. This can have important implications for the
‘atmosphere’ in such rooms: they can have a more informal feel.
The injecting rooms are more clinical and, if large numbers of
users are processed over the course of the day, medical
emergencies are inevitably quite common. Such projects are
clearly preventing overdose incidents from progressing to life-
threatening stages.
Public order vs public health
Model 2 was set up with public order as the overriding priority.
Models 1 and 3 have combined health and public order aims. If
public order is the main aim, it becomes important to retain users
for as long as possible within the project and to ensure that users
have somewhere to go at all hours of the day. The day care
approach exemplified by model 2 shows how this can be done.
Open access vs targeted
Targeted projects such as model 2 allow projects to run within a
more clearly defined set of aims. However, users who fall outside
the criteria and who may be in danger are excluded. Model 3
effectively excludes some users on account of the rules it imposes.
Model 1 is the most open to all injectors.
Integrated vs specialist
Model 3 shows how a range of provision, including consumption
rooms, can be kept under one roof. Model 1 is at the other end of
the continuum, focusing almost exclusively on ensuring that users
inject safely.
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DCRs in the UK
What do these considerations mean for DCRs in this country? This
section addresses each of the dimensions referred to above in
turn.
Injecting vs smoking
As has been concluded in Chapter 3, the UK has a relatively large
population of injecting drug users and it therefore seems logical
that any initiative here would need to address injecting, which is
associated with the most serious health risks. Nevertheless, as has
also been discussed, crack smoking has increased in prevalence
and is a serious problem that should not be ignored. Moreover,
there are serious concerns surrounding current services’ ability to
attract primary crack users in the UK (Home Office, 2002b). A
crack smoking room might provide one way to bring in crack users
who are otherwise out of contact with services.
An important question here is the extent to which smoking and
injecting rooms can be combined within a single project. In the
Netherlands, where the majority of problem drug users smoke their
drugs, having both types of room located next to each other
appears to have worked well. In Germany and Switzerland too,
projects are increasingly adding smoking rooms. Some of the
users involved in the IWG’s consultation referred to the importance
of separating crack smokers from injectors. The difference in the
effects caused by the drugs was thought to carry the potential to
cause problems among mixed groups of users. Were pilot injecting
and smoking rooms to be set up in the UK, there may be merit in
positioning them in separate locations, especially if a particular
subpopulation of crack smokers were to be targeted, such as sex
workers or particular ethnic groups.
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Public order vs public health
As we have seen in Chapter 3, the UK suffers from both public
nuisance and public health problems associated with drug use.
Both constitute important arguments for the introduction of DCRs in
this country. However, while health problems will occur in any
population of marginalised users around the country, there seems
to be more variation in the level of public nuisance. In order to
evaluate the extent to which DCRs can impact on public nuisance,
it would be important to site DCRs in areas associated with high
levels of such nuisance.
Open access vs targeted
Model 2 describes a highly targeted approach, whereby homeless
users causing public nuisance are selectively given access to a
project. Such an approach allows a project to tailor its design and
procedures to the needs of the targeted group. In the case of
model 2, this involved providing attractive day care facilities. If it
were to be decided that UK DCRs should focus primarily on the
most marginalised, homeless drug users, this type of approach
seems sensible. However, as the IWG research on NSP clients
revealed, a significant proportion of public injectors live in their own
accommodation. In this particular study just under a quarter of the
public injectors were in this category. As public injectors endanger
themselves whatever their accommodation status (and also cause
public nuisance), the IWG concludes that projects should target not
only homeless users in this way but public injectors more generally.
Integrated vs specialist
DCRs in Europe have frequently been added to existing services
rather than being designed as a stand-alone facility. The IWG sees
great benefit in consumption rooms being part of wider services for
drug users. First, every effort needs to be made to move users on
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from their current drug use: where windows of opportunity arise for
treatment, these need to be seized quickly. Having other services
sharing the same site gives the potential to respond with greater
speed. Second, a key aim of DCRs must be to further integrate
marginalised users. Provision of advice on accommodation,
benefits and employment should be an important part of such an
approach. In Zurich, social reintegration is now seen as one of the
foremost goals and there are close links with the city’s housing
services. Third, drug users suffer from a range of health problems,
some associated with their drug use but others associated with
their general lifestyles. Provided sufficient numbers of users are
attracted, the provision of primary health care on site is likely to
prevent problems escalating and divert users from expensive
hospital treatment. Finally, as discussed in the previous chapter,
appending DCRs to existing services is likely to have the least
negative impact on local communities.
Structure, location and minimum standards
There are strong arguments for setting up DCRs within existing
drug services. However, there remains the question of which
services. The IWG has discussed at length the possibility of DCRs
being appended to hostel accommodation. Where hostels do not
allow drug use to take place on the premises,3 residents are asked
to leave the hostel in order to take their drugs. This will often mean
that users end up injecting in public places nearby. We heard
reports of fatal overdoses occurring as a direct result of hostel
residents having to inject off the premises in dangerous and
isolated locations. However, the IWG has also heard from local
project workers that some hostels have recently started to allow
drug use to take place within them. This is happening as a
consequence of the Government’s decision (discussed in the last
chapter) to repeal a proposed amendment to section 8(d) of the
MDA, as a result of which it only remains an offence for an
occupier or manager of premises to ‘knowingly permit or suffer’ the
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smoking of cannabis or ‘prepared opium’ on the premises. If hostel
users are allowed to use drugs in their own rooms or dormitories,
to some extent this may obviate the need for a DCR. Certainly,
given the confusion surrounding hostel policies, the IWG does not
think that it can recommend the piloting of DCRs in this context.
However, it is strongly recommended that there is a review of
hostel policies and practices in this area. Allowing users to inject in
their own rooms may be the lesser of a number of possible evils
but if users are allowed to inject alone and unsupervised behind a
closed door, there remains a real risk of overdose fatalities.
The IWG sees greater merit in setting up DCRs as adjuncts to
NSPs. As we have seen from the NSP user survey undertaken for
the IWG, a considerable proportion of NSP users appear to inject in
public places. It also appears from this research that NSPs attract
considerable numbers of hostel users and rough sleepers. A busy
NSP already brings a lot of users to its door and the addition of a
DCR is therefore unlikely to make a great difference to the flow of
users through a local community. Finally, the positioning of a DCR in
this context would bring together harm reduction services under one
roof. This prevents any ‘contamination’ effect of mixing approaches
that aim to reduce the risks associated with illicit drug use with those
aiming to stem their use or substitute their use with other drugs.
However, were DCRs to be set up within NSPs, the IWG would
want to see their resources considerably boosted, in order to
deliver the type of ‘integrated’ services referred to above. A recent
survey of needle exchange services has shown great variation in
the range of additional services provided by such projects (NTA,
forthcoming). It would be imperative to situate DCRs in facilities
which provide a range of services, including wound care and
overdose prevention advice. The IWG also concludes that, while
the main emphasis should be on making users safer, there should
also be a commitment to helping users to move on to treatment if
they are able to do so. The IWG does not accept that there is an
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unbreachable divide between harm reduction and treatment or
abstinence-oriented goals, and staff working in DCRs should have
the flexibility to help their clients in a variety of different ways.
While DCRs located in NSPs are likely to work with some of the
most chronic, damaged and marginalised users, recovery will
always be a possibility.
Given the potential for DCRs to prevent drug-related deaths, there
is a strong argument for setting them up in areas associated with
particularly high rates of drug-related death. It would be vitally
important to inform users released from prison about the existence
of such projects. It would also be important to set them up in areas
with a good history of interagency working: particularly between the
police and drug agencies. IWG members were impressed by the
extent of co-operation and trust that existed between agencies
in the cities visited abroad.
Finally, there would need to be a clear set of minimum standards
forming part of the clinical governance arrangements for any DCR.
These would need to be strictly adhered to and regularly audited.
They would cover issues such as the minimum number of trained
staff required to supervise injecting and intervene in drug-related
emergencies.
Pilots
Given the above considerations, the IWG concludes that there are
strong arguments for DCRs initially being piloted in NSPs. Should
they prove to work well, this would provide a model which could be
replicated relatively easily elsewhere. There are other DCR models
that might be tried in the UK at some point in the future. The IWG
believes that there is potential in the idea of introducing DCRs for
smoking crack, which would aim to attract marginalised users who
are currently not attending any other services. However, at this
stage, this idea requires further research and exploration.
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Evaluation
The IWG views it as imperative that these pilot DCRs would be
properly evaluated. Detailed process and outcome evaluations
would need to be conducted. Perhaps most important, and
sometimes overlooked, would be the need to collect detailed data
before pilots were to commence and comparative data from sites
where DCRs were not to be introduced. These data should include
a user survey, community survey (including local residents and
businesses) and statistics on ambulance call-outs, hospital
treatment and drug-related deaths. It would also be important to
map the flows of users through the local area and to conduct a
more qualitative assessment of the history and nature of drug use
in the locality. Police intelligence on local drug markets will also be
vitally important information which will help evaluators to judge how
things may have changed after the introduction of a DCR but
should also help in deciding on the location of the pilot project.
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The initial aim of the IWG was to take an objective and evidence-
based approach to the question of whether DCRs could have a
significant impact on the private and public harms associated with
drug use in the UK. It then went on to look at the barriers to setting
up DCRs in the UK and the possible models that might be applied.
In looking at these issues over a 20-month period, the IWG has
identified a number of important findings and reached some key
conclusions.
Key findings and conclusions
The policy context
 The IWG welcomes the increased emphasis in the
Government’s Drug Strategy on harm reduction and the
existence of strategic aims that reflect this emphasis. A number
of these aims are directly addressed by DCRs.
Harms associated with drug use
 The UK has a substantial population of injecting drug users and
the highest number of drug-related deaths in Europe.
 There is a high, and rising, prevalence of hepatitis C among
drug injectors. Hepatitis B is also a serious concern.
 While lower than in many other countries, HIV prevalence
appears to be increasing among injecting users.
 Many users infected with blood-borne viruses are unaware of
their infection.
7 Summary, conclusions and
recommendations
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 While hepatitis B can be prevented through vaccination, fewer
than half the population of injecting drug users have been
vaccinated.
 Abscesses, cellulitis and other infections are common among
injectors, leading to frequent hospital treatment.
 There is a substantial population of high-risk, homeless,
injecting drug users, based in hostels or rough sleeping. They
inject frequently in public places and are therefore associated
with a lot of public nuisance.
 Evidence from research undertaken for the IWG showed that
42 per cent of a sample of 398 needle exchange users had
injected in a public area at least once in the previous week.
 A significant minority of injectors who live in their own home
also inject in public places. One in four of the needle exchange
users who lived in their own home had injected in public in the
previous week.
 In England alone, the number of drug injections occurring in
public places is likely to be in the order of tens of thousands per
month.
 In addition to the physical risks to themselves, users forced to
inject in run-down, unhygienic and dangerous public areas are
likely to experience anguish, loss of dignity and low self-worth.
 Large quantities of syringes and drug-related litter are dropped
in public places across the UK, causing considerable impact on
local residents and businesses.
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Are DCRs effective?
 DCRs prevent drug-related deaths by providing early
intervention in potentially fatal overdose incidents.
 They are successful in providing on-site medical care and
referring users to off-site medical services. The IWG is
therefore confident that well-run DCRs improve the general
health of users.
 DCRs can reduce sharing of injecting equipment and are likely
to reduce the transmission of blood-borne viruses but the latter
has not yet been demonstrated and is very difficult to prove.
 There is no evidence that DCRs either increase or decrease an
individual’s drug use.
 There is good evidence showing DCRs to be associated with a
reduction in injecting in public places. They can also lead to a
reduction in discarded used syringes and drug-related litter.
 DCRs do not appear to act as a magnet for users from outside
the local area. Most of those who use DCRs are local drug
users.
 DCRs are effective at attracting local homeless and other
socially excluded drug users.
 There is no evidence that DCRs either increase or decrease
levels of acquisitive crime. However, this is unsurprising as
DCRs do not provide prescription drugs and cannot therefore
directly affect crime committed to obtain drugs.
 To the extent that DCRs are successful in providing access to
structured treatment and other interventions aimed at social
integration, they may have an indirect impact on crime levels.
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 Some DCRs have been periodically associated with local public
disorder and dealing. These problems have been successfully
dealt with through close co-operation between the key
agencies, including the police, and strict rules governing
behaviour in and around the DCR.
 While other services address some of the harms targeted by
DCRs, the IWG concludes that DCRs offer the unique potential
to ensure safer, on-site injecting and thereby directly prevent
health problems, drug-related deaths and drug-related
nuisance.
Would DCRs have an impact in the UK?
 The IWG concludes that well-designed and well-implemented
DCRs would have an impact on some of the serious drug-
related problems experienced in the UK.
Barriers and concerns
 The IWG does not regard the UN Conventions as imposing a
manifest embargo on the implementation of DCRs in this
country.
 There are a number of potential legal obstacles within United
Kingdom law. Many of these could be addressed through
properly enforced rules. However, some areas of risk would
remain.
 The weight and implication of various ethical concerns are hard
to judge impartially. The IWG would welcome debate on these
issues. However, some of these questions are probably best
addressed through evaluation of pilot projects.
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DCR pilots
 There is a wide variation across the eight countries that have
introduced DCRs in how they are designed and run.
 There are strong arguments for DCRs in the UK focusing on
drug injecting, but being otherwise open access, targeting both
public health and public order objectives and being run within
existing services.
 Further thought needs to be given to the idea of DCRs which
target primary crack smokers, a group often out of contact with
services (such rooms might also include heroin smoking).
 Evaluation of pilot projects would be essential and would need
to be properly resourced.
Recommendations
The Independent Working Group on Drug Consumption Rooms
makes the following key recommendations:
 The IWG recommends that a number of pilot drug consumption
rooms be set up in the UK. These projects should be founded
on local accords between the key agencies and therefore need
to be in areas where there is already considerable local support
for the idea.
 Ideally, this piloting process would be supported and co-
ordinated by central government. However, if the Government
is unable to play this role, the IWG hopes that local agencies
will be able to devise local schemes where it is in the public
interest to do so.
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 The IWG recommends that initial pilots should consist of
injecting rooms only. Well-run needle and syringe exchange
projects (NSPs) appear to offer a promising location for setting
up DCRs in the UK and the IWG recommends that pilot projects
are set up in this context.
 There are a number of other approaches that the IWG thinks
are worthy of exploration. In particular, there appears to be
considerable potential for developing DCRs for primary crack
smokers, a rapidly growing population, the majority of whom
are out of contact with services. This idea requires further
research and development.
 DCR pilots should form part of an integrated local drug service,
providing the opportunity for users to give up or reduce their
drug use, as well as making their use safer.
 DCRs need to provide a sufficient number of trained staff to be
able to intervene in drug-related emergencies, such as
overdose events. They also need to be able to provide basic
on-site medical treatment, such as wound care.
 There should also be access to, and where possible direct
provision of, advice on accommodation, benefits and
employment, hygiene and self-care. Washing and laundering
facilities should also be provided.
 DCRs should be set up in areas experiencing significant
problems with public drug use and overdose deaths. They
should also be set up in areas where there is genuine support
for the idea across the relevant agencies and a strong potential
for interagency working. The support of the local police will be
crucial to the success of any pilot project.
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 Local communities and stakeholders should be closely involved
in the development of pilot projects.
 These pilots must be carefully evaluated and the calculation of
the cost of this piloting exercise should include resources for an
extensive evaluation, which would include local community and
user surveys and an assessment of cost-effectiveness.
 Although legislative change would be the safer option for
piloting DCRs in the UK, there are arguments for delaying any
such change until the pilots have been evaluated and their
effectiveness assessed. Amending or introducing legislation
would prove a wasted effort if the pilots were then shown to be
ineffective. Furthermore, the implementation and operation of
pilot projects may provide valuable insights into the particular
type of legal protection that might be required.
 However, it is clear that there would be some dangers in setting
up DCRs under the current law. These dangers would be
minimised by the imposition of a set of clear rules governing the
behaviour of users and staff. To this end, it is recommended
that a set of minimum standards is developed which forms part
of the clinical governance for pilot DCRs and is subject to
regular audit.
The IWG is keen to see a public debate take place on its
recommendations and on the issue of DCRs more generally. It is
hoped that the use of misleading terms like ‘shooting galleries’ and
‘drug dens’ can be avoided in this debate. DCRs represent a
serious policy option, with clear public health and public order
objectives, that has been implemented in eight countries around
the world. It would also be an initiative in line with the UK’s record
of being in the forefront of developments in the field of harm
reduction. The IWG regards the idea as deserving proper
consideration and informed debate.
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Conclusion
DCRs certainly cannot provide the answer to all the ills associated
with problem drug use. Furthermore, they seem only to offer a
palliative when everyone would prefer to see a cure. However,
while the IWG holds the view that no drug intervention should ever
give up on the possibility of treatment and, ultimately, abstinence,
there are a large number of problem users in this country who are,
for whatever reason, currently unable or unwilling to control or
reduce their use. The IWG considers DCRs to be a rational and
overdue extension to the harm reduction policy that has produced
substantial individual and public benefits in the UK. They offer a
unique and promising way to work with the most problematic users,
in order to reduce the risk of overdose, improve their health and
lessen the damage and costs to society.
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Chapter 1
1 The term ‘drug consumption room’ is used to describe an
official, protected space for the hygienic consumption of pre-
obtained drugs in a non-judgemental environment, under the
supervision of trained staff (adapted from Hedrich, 2004).
2 Chapter X, Decree-Law 183/2001, http://www.drogas.pt/media/
legislacao/english/dl183_01.pdf.
3 Personal communication, João Goulão, Chairman, Institute on
Drugs and Drug Addiction, Lisbon, Portugal.
Chapter 2
1 The EMCDDA is a decentralised agency of the European
Union, its central role being to provide the EU and its member
states with objective, reliable and comparable information on
drugs and drug addiction.
2 Evaluation of the Government’s success in this respect will not
be possible until later in 2006, when figures on deaths in 2004
become available.
3 The six supporting IWG papers are published on the JRF
website at http://www.jrf.org.uk/bookshop/
details.asp?pubid=749
Chapter 3
1 This differentiation is not without complications, in that all
private harms are likely to have public consequences. For
example, overdoses will cost society money in terms of
emergency services, hospital treatment etc. However, the
division is useful in separating those harms that have a
Notes
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predominant impact in one sphere from those that have a
predominant impact in the other.
2 Defined by EMCDDA as ‘injecting drug use or long duration or
regular use of opiates, cocaine and/or amphetamines’ (http://
www.emcdda.eu.int/?nnodeid=1372).
3 The prevalence estimates for Scotland and Northern Ireland
were obtained using the capture–recapture method whilst the
estimates for England were produced on the basis of combining
capture–recapture estimates for certain areas (Brighton,
Greater Manchester, Liverpool, and parts of London) with
additional multivariate indicator estimation work in other parts of
England (Hickman et al., 2004a, 2004b).
4 One third of a sample of 398 drug users attending needle and
syringe exchange projects surveyed in a study carried out for the
IWG were living in hostel accommodation (see boxed information
on this study later in this section and Hunt et al., forthcoming).
5 Assuming there are around 93,000 injecting drugs users in
England (Frisher et al., 2006) and, if at least 20 per cent of
injecting drug users are in contact with NSPs (Hickman et al.,
2004b), this suggests somewhere in the region of 18,600
injecting drug users in contact with NSPs. Assuming that they
are similar to the sample surveyed in the IWG research, we
would expect 42 per cent of this sample to have injected in
public at least once in any given week: a total of 7,812. On a
monthly basis, this would be approximately 31,000 injections
per month. Moreover, a substantial number of injectors are
injecting in public many times a week and there are also,
inevitably, people injecting in public places who do not use NSP
programmes. The IWG is therefore confident in concluding that,
in England alone, tens of thousands of injecting episodes per
month occur in public places.
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Chapter 4
1 Naloxone is an opioid antagonist which blocks the opioid
receptors in the brain and thereby blocks the effect of heroin
and other opioids.
2 The rate of overdose intervention in the Vancouver Insite
project was 1.3 per 1,000 injections, falling within this range.
Chapter 5
1 Political Declaration: Guiding Principles of Drug Demand
Reduction and Measures to Enhance International Cooperation
to Counter the World Drug Problem, Special Session of the
General Assembly Devoted to Countering the World Drug
Problem Together, 8–10 June 1998.
2 Schedule IV drugs include cannabis and heroin.
3 Swiss Institute of Comparative Law, Use of Narcotic Drugs in
Public Injection Rooms under Public International Law, AVIS
99-121c, 7 January 2000.
4 Where smoking and injecting facilities coexist, we have been
struck by the vigorous efforts that project workers make to deter
transitions from smoking to injecting.
5 Switzerland has only signed the first two of the three
Conventions.
6 The NTA guidance on the prescription of injectable heroin
states that eligible clients should have a ‘protracted history
(>3 years) of heroin dependence’, have failed to respond to at
least six months of oral maintenance treatment and be willing to
comply with supervision and monitoring arrangements (NTA,
2003).
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Chapter 6
1 There is very little information on the Luxembourg project that
had only very recently been set up at the time of writing.
2 However, there may be a danger that a low rate of overdose
incident will lead to a lack of preparedness on the part of staff –
and may therefore make overdose incidents more dangerous in
such circumstances.
3 This is reportedly the most common situation, although the IWG
was frustrated by the dearth of official information.
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Aims
1 To take an objective and evidence-based approach to the
following question, drawing on both the national and
international literature: ‘Is there the potential for DCRs to have a
significant impact on the private and/or public harms associated
with drug use in the UK?’
2 Should the IWG decide that there is such potential:
 to consider the pros and cons of different models
 to identify the legal, political and practical obstacles to
implementation and seek solutions
 to make recommendations for the development and
evaluation of appropriate demonstration projects.
3 To publish an accessible report summarising the evidence, the
arguments and the recommendations.
Membership
Members have been identified and approached on account of their
personal expertise in a relevant field and have joined the group in
an individual capacity, rather than as representatives of their
organisations.
Timescale
The timescale will need to be flexible. If, after considering evidence
relating to the first aim, the Working Group decides that there is no
need for drug consumption rooms in the UK, then the Working
Group would end at this point and a report would be published.
This would mean a short timescale. Should the Working Group
decide that there does appear to be a need, a much longer
timescale would be required to consider evidence relating to the
second aim. In this case, it is envisaged that the process would
Appendix: Terms of reference
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take around 18 months, with a view to publishing the report at the
end of 2005. This would mean producing an agreed final report by
the end of September 2005.
Number of meetings
The intention is to hold meetings every three months. Should the
Working Group go on to consider the second aim, this could mean
around eight meetings over the 18-month period (including a
meeting after the report was agreed to discuss dissemination/
publicity).  However, we will need to be flexible – and there may
need to be more or less meetings at particular points in time.
Organisation of meetings
Papers will be circulated a week before the meeting, to allow
members to come prepared for discussion. While written papers
will form the main business of meetings, it is also expected that
experts will be invited to talk to the Working Group on particular
issues. Minutes of each meeting will be taken, written up and
circulated.
Role of the Joseph Rowntree Foundation
The Foundation is supporting the Working Group financially and
one of the Working Group members works for the Foundation.
However, the views expressed in the report will be those of the
Working Group as a whole and will therefore be largely
independent of the Foundation (in the same way that views
expressed in JRF-funded research reports are the views of the
researchers, rather than the Foundation). However, it is expected
that the report will be published by the Foundation and a press
release produced by the Foundation, in association with the
Working Group.
